2026

HALF-YEAR FINANCIAL REPORT

BIOMÉRIEUX

bioMérieux
French joint stock company (*société anonyme*) with share capital of €12,029,370
Headquarters : Marcy l'Étoile (69280)
673 620 399 Lyon Trade and Companies Register

INTERIM FINANCIAL REPORT
FOR THE SIX MONTHS ENDED JUNE 30, 2026

CONTENTS

I. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AT JUNE 30, 2026

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AT JUNE 30, 2026

Consolidated profit & loss statement

In millions of euros	Notes	2026 (6 months)	2025 (6 months)
REVENUE	**13**	**1,964.6**	**2,043.8**
Cost of sales		-866.4	-876.9
GROSS PROFIT		**1,098.2**	**1,166.9**
OTHER OPERATING INCOME AND EXPENSES	**14**	**16.9**	**23.2**
Selling and marketing expenses		-390.3	-407.8
General and administrative expenses		-154.0	-161.0
Research and development		-257.4	-249.4
TOTAL OPERATING EXPENSES		**-801.8**	**-818.2**
Amortization and impairment of intangible assets related to acquisitions and acquisition-related costs	15	-14.2	-163.2
OPERATING INCOME BEFORE NON-RECURRING ITEMS		**299.1**	**208.7**
Other non-recurring income and expenses from operations	16	0.6	0.5
OPERATING INCOME		**299.7**	**209.2**
Cost of net financial debt	17.2	1.0	9.7
Other financial income and expenses	17.3	-6.1	-5.7
Income tax	18	-68.8	-52.6
Share in net income of associates		0.0	0.0
CONSOLIDATED NET INCOME		**225.8**	**160.6**
Share attributable to non-controlling interests		-0.3	-0.4
ATTRIBUTABLE TO THE PARENT COMPANY		**226.1**	**161.0**
Basic earnings per share		€1.92	€1.36
Diluted (net) earnings per share		€1.91	€1.35

Statement of comprehensive income

In millions of euros	Notes	2026 (6 months)	2025 (6 months)
Consolidated net income		**225.8**	**160.6**
Items to be reclassified in income		**95.9**	**-359.6**
Fair value gains (losses) on financial hedging instruments	(a)	-1.3	8.0
Tax effect		0.2	-2.0
Movements in cumulative translation adjustments	(b)	97.0	-365.7
Items not to be reclassified to income		**-1.5**	**4.1**
Fair value gains (losses) on financial assets	(c)	-1.8	0.5
Tax effect		0.0	0.2
Remeasurement of employee benefits	(d)	0.4	4.5
Tax effect		-0.1	-1.1
TOTAL OTHER COMPREHENSIVE INCOME		**94.4**	**-355.6**
COMPREHENSIVE INCOME		**320.2**	**-195.0**
Share attributable to non-controlling interests		0.0	-2.1
ATTRIBUTABLE TO THE PARENT COMPANY		**320.2**	**-192.9**

(a) Change in the effective portion of financial hedging instruments.

(b) The change in translation differences in 2026 is mainly related to the appreciation of the dollar against the euro, compared with a depreciation of the dollar in 2025.

(c) Fair value gains (losses) on financial assets concern shares in non-consolidated companies for which the Group has opted to recognize fair-value changes in other comprehensive income not to be reclassified to profit and loss (see Note 5).

(d) See Note 11.3.

Consolidated balance sheet

ASSETS *In millions of euros*	Notes	**06/30/2026**	**12/31/2025**
Goodwill	3.2	757.1	727.8
Other intangible assets	3.3	415.1	401.5
Property, plant and equipment	4.1	1,563.8	1,515.9
Right-of-use assets	4.2	145.1	141.3
Non-current financial assets	5	121.1	128.7
Investments in associates		0.7	0.7
Other non-current assets		11.2	10.3
Deferred tax assets		84.3	108.1
NON-CURRENT ASSETS		**3,098.4**	**3,034.3**
Inventories and work-in-progress	7	975.3	959.7
Trade receivables and assets related to contracts with customers	8	715.3	766.2
Other operating receivables		192.3	178.5
Current tax receivables		34.7	47.8
Non-operating receivables		19.8	18.4
Cash and cash equivalents	12.4	657.7	569.8
CURRENT ASSETS		**2,595.2**	**2,540.4**
ASSETS HELD FOR SALE	**6**	**0.0**	**0.0**
TOTAL ASSETS		**5,693.6**	**5,574.7**

LIABILITIES *In millions of euros*		**06/30/2026**	**12/31/2025**
Share capital	10.1	12.0	12.0
Additional paid-in capital and reserves	10.2	4,058.8	3,692.6
Net income for the period		226.1	397.5
GROUP EQUITY		**4,297.0**	**4,102.1**
MINORITY INTERESTS		**2.1**	**3.9**
EQUITY OF CONSOLIDATED COMPANIES		**4,299.1**	**4,106.0**
Long-term borrowings and debt	12.4	188.6	330.0
Deferred tax liabilities		24.9	26.0
Provisions	11	53.4	48.0
NON-CURRENT LIABILITIES		**266.9**	**404.0**
Short-term borrowings and debt	12.4	233.2	131.4
Provisions	11	46.0	44.3
Trade payables		252.1	262.1
Other operating payables		514.3	539.4
Current tax payables		26.5	18.3
Non-operating payables		55.6	69.2
CURRENT LIABILITIES		**1,127.6**	**1,064.7**
LIABILITIES RELATED TO ASSETS HELD FOR SALE	**6**	**0.0**	**0.0**
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		**5,693.6**	**5,574.7**

Consolidated cash flow statement

In millions of euros	Notes	June 2026	June 2025	
Consolidated net income		**225.8**	**160.6**	
- Cost of net financial debt	17.2	-1.0	-9.7	
- Other financial income and expenses	17.3	6.1	5.7	
- Income tax expense	18.2	68.8	52.6	
- Net additions to operational depreciation and amortization – non-current provisions		127.8	123.9	
- Amortization and impairment of intangible assets related to acquisitions	15	12.8	162.0	
EBITDA	**12**	**440.3**	**495.1**	
Other non-recurring income and expenses from operations (excluding non-recurring provisions for impairment, asset impairment losses, and capital gains (losses) on disposals of fixed assets)	16	-3.9	0.0	
Other financial income and expenses *(excluding provisions and disposals of non-current financial assets, and the impact of hyperinflation on OCI)*	17.3	-2.7	-3.8	
Net additions to operating provisions for contingencies and losses	11.2	0.0	3.3	
Fair value gains (losses) on financial instruments		-0.1	2.1	
Share-based compensation		7.3	12.6	
Capital gains and losses on disposals		2.5	2.6	(d)
Elimination of other non-cash or non-operating income and expenses		**3.1**	**16.7**	
Change in inventories		7.2	-24.9	
Change in trade receivables		63.4	58.5	
Change in trade payables		-9.6	-28.8	
Change in other operating working capital		-41.5	-79.7	
Change in operating working capital requirement (a)	**12.2**	**19.4**	**-74.8**	
Other non-operating working capital		0.7	-0.5	
Change in non-current non-financial assets and liabilities		0.4	-3.0	
Change in working capital requirement		**20.5**	**-78.3**	
Income tax paid	**12.2**	**-28.1**	**-123.2**	
Cost of net financial debt	**17.2**	**1.0**	**9.7**	
NET CASH FROM OPERATING ACTIVITIES		**436.8**	**320.1**	(d)
Disbursements on purchases of property, plant and equipment and intangible assets (b)	3.3 and 4.1	-139.5	-152.7	
Proceeds from disposals of property, plant and equipment and intangible assets		1.6	2.2	(d)
Proceeds from other non-current financial assets		0.0	0.5	
FREE CASH FLOW (c)		***299.0***	***170.1***	
Disbursements related to non-consolidated and equity-accounted securities		0.0	-0.6	
Impact of changes in the scope of consolidation	1.1.1	-27.8	-131.2	
NET CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES		**-165.6**	**-281.8**	(d)
Purchases and sales of treasury shares		-19.3	16.4	
Dividends paid to owners		-115.2	-106.1	
Cash flows from new borrowings	12.4	0.6	34.2	
Cash flows from loan repayments	12.4	-64.6	-21.0	
Change in interests without acquisition or loss of control	1.1.2	-0.7	0.0	
NET CASH USED IN FINANCING ACTIVITIES		**-199.3**	**-76.5**	
NET CHANGE IN CASH AND CASH EQUIVALENTS		**71.9**	**-38.2**	
NET CASH AT BEGINNING OF PERIOD		**565.1**	**442.1**	
Impact of currency changes on net cash and cash equivalents		17.9	-46.9	
NET CASH AT END OF PERIOD		**654.9**	**357.0**	

(a) *Including allocations (reversals) of short-term provisions.*

(b) *Including advances and prepayments to fixed asset suppliers.*

(c) *Available free cash flow consists of cash flows related to the activity and those related to capital expenditure excluding net cash from acquisitions and disposals of subsidiaries.*

(d) *A reclassification was carried out during the comparative period to report the gains and losses on the disposal of fixed assets separately, with no impact on free cash flow.*

Comments on the changes in the Group's net cash and cash equivalents are provided in Note 12.

Change in consolidated shareholders' equity

In millions of euros	Attributable to the parent company										Attributable to minority interests
	Share capital	Consolidated additional paid-in capital and reserves [a]	Cumulative translation adjustments	Changes in fair value [b]	Actuarial gains and losses [c]	Treasury shares	Share-based compensation	Total additional paid-in capital and reserves	Net income	**Total**	**Total**
EQUITY AT DECEMBER 31, 2025	**12.0**	**4,010.2 [h]**	**-145.6 [i]**	**-124.3**	**-43.6**	**-40.0**	**35.9**	**3,692.5**	**397.5**	**4,102.1 [h]**	**3.9**
Total comprehensive income for the period			96.7	-2.9	0.3			94.2	226.1	**320.2**	**0.0**
Appropriation of prior-period net income		397.5						397.5	-397.5	**0.0**	
Dividends paid (d)		-115.2						-115.2		**-115.2**	
Treasury shares		-2.0				-16.8		-18.7		**-18.7**	
Share-based compensation (e)							7.3	7.3		**7.3**	
Changes in ownership interests (f)		0.6						0.6		**0.6**	**-1.7**
Other changes (g)		-4.4		5.1			0.0	0.7		**0.7**	
EQUITY AT JUNE 30, 2026	**12.0**	**4,286.6 [h]**	**-48.9 [i]**	**-122.1**	**-43.2**	**-56.8**	**43.2**	**4,058.8**	**226.1**	**4,297.0 [h]**	**2.1**

(a) Of which additional paid-in capital: €74.0 million at June 30, 2026, and at December 31, 2025.

(b) Mainly including changes in the fair value of Oxford Nanopore Technologies and hedging instruments.

(c) Actuarial gains and losses on employee benefit obligations arising since the effective date of IAS 19R.

(d) Dividends per share: €0.98 in 2026, compared with €0.90 in 2025. Shares not qualifying for dividends amounted to €669,136 at June 30, 2026 compared with €373,069 at December 31, 2025.

(e) The fair value of benefits related to free share grants is recognized over the vesting period.

(f) Corresponds to the buyout of minority interests in Hybiome (3.3%).

(g) In 2026, this change mainly corresponded to the reclassification related to the acquisition of Accellix from changes in fair value to reserves.

(h) Of which bioMérieux SA distributable reserves including net income for the period: €1,812 million in 2026 compared with €1,607 million in 2025.

(i) See Note 10.2 Cumulative translation adjustments.

In millions of euros	Attributable to the parent company										Attributable to minority interests
	Share capital	Consolidated additional paid-in capital and reserves [a]	Cumulative translation adjustments	Changes in fair value [b]	Actuarial gains and losses [c]	Treasury shares	Share-based compensation	Total additional paid-in capital and reserves	Net income	**Total**	**Total**
EQUITY AT DECEMBER 31, 2024	**12.0**	**3,666.9** [h]	**221.7** [i]	**-69.8**	**-48.1**	**-42.9**	**32.8**	**3,760.6**	**432.2**	**4,204.9** [h]	**6.1**
Total comprehensive income for the period			-364.0	6.8	3.4			-353.9	161.0	**-192.9**	**-2.1**
Appropriation of prior-period net income		432.2						432.2	-432.2	**0.0**	
Dividends paid (d)		-106.1						-106.1		**-106.1**	
Treasury shares		2.7				12.7		15.5		**15.5**	
Share-based compensation (e)							12.6	12.6		**12.6**	
Changes in ownership interests		0.0						0.0		**0.0**	**0.0**
Other changes (f)		16.8		-16.9			0.0	-0.1		**-0.1**	
EQUITY AT JUNE 30, 2025	**12.0**	**4,012.6** [g]	**-142.3** [h]	**-80.0**	**-44.7**	**-30.2**	**45.4**	**3,760.9**	**161.0**	**3,933.9** [h]	**4.0**

(a) Of which additional paid-in capital: €74.0 million at June 30, 2025, and at December 31, 2024.

(b) Mainly including changes in the fair value of Oxford Nanopore Technologies, SpinChip and hedging instruments.

(c) Actuarial gains and losses on employee benefit obligations arising since the effective date of IAS 19R.

(d) Dividends per share: €0.90 in 2025, compared with €0.85 in 2024. Shares not qualifying for dividends amounted to €294,015 at June 30, 2025 compared with €439,722 at December 31, 2024

(e) The fair value of benefits related to free share grants is recognized over the vesting period.

(f) In 2025, this change corresponded to the reclassification of the disposal of SpinChip from changes in fair value to reserves.

(g) Of which bioMérieux SA distributable reserves including net income for the period: €1,607 million in 2025 compared with €1,261 million in 2024.

(h) See Note 10.2 Cumulative translation adjustments.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AT JUNE 30, 2026

bioMérieux is a leading international diagnostics group that specializes in the field of *in vitro* diagnostics for clinical and industrial applications. The Group designs, develops, manufactures and markets diagnostic systems (reagents, instruments and services). bioMérieux is present in more than 160 countries through its locations in 46 countries and a large network of distributors.

The parent company, bioMérieux, is a French joint stock company (société anonyme) whose headquarters are located in Marcy-l'Étoile (69280) and whose shares are listed on Euronext Paris, compartment A.

The condensed interim consolidated financial statements were approved by the Board of Directors on July 27, 2026. They are presented in millions of euros. They have been subject to a review by the Statutory Auditors.

The risk factors applicable to the bioMérieux Group are described in section 4 of the 2025 Universal Registration Document filed with the French financial markets authority (*Autorité des marchés financiers – AMF*) on March 16, 2026.

1. SIGNIFICANT EVENTS AND CHANGES IN THE SCOPE OF CONSOLIDATION FOR THE HALF-YEAR

1.1. CHANGES IN THE SCOPE OF CONSOLIDATION

1.1.1 Acquisition of Accellix

On January 22, 2026, bioMérieux acquired 100% of Accellix, a U.S. company that has developed rapid automated flow cytometry solutions for cell and gene therapy quality control.

The acquisition of the remainder of Accellix's capital follows its prior purchase of a non-controlling interest of 11%. The purchase of 89% of the company's capital during the period represented a cash outflow of €27.8 million (excluding acquisition-related costs and net of cash acquired).

Impact of the acquisition on the consolidated financial statements

The subsidiary has been fully consolidated since the date of its acquisition. The ongoing analysis of the purchase price allocation led to the recognition, at the acquisition date, of a technology and customer relations net of deferred tax liabilities for €18.2 million, inventory changes net of deferred tax liabilities for €0.7 million and provisional goodwill of €14.1 million. This goodwill was assigned to the Industrial Applications Cash Generating Unit.

The technology is amortized over 15 years, starting from the acquisition date, with a value €0.7 million at June 30, 2026.

The costs incurred in connection with this transaction amounted to €1.2 million and were recorded under "Amortization and impairment of intangible assets related to acquisitions and acquisition-related costs" within operating income before non-recurring items.

Accellix generated an operating loss of €5 million in the first half of 2026, excluding restructuring costs (€1.3 million) and amortization of technology (€0.7 million). Since the impact of integrating Accellix into the Group's financial statements is not significant, no pro forma information has been provided for the comparative fiscal years.

As mentioned above, the purchase price allocation is deemed provisional at June 30, 2026 and may be adjusted until January 22, 2027.

1.1.2 Other changes in the scope of consolidation

In the first half of 2026, bioMérieux acquired an additional 3.3% stake in Suzhou Hybiome Biomedical Engineering Co. Ltd for approximately €0.7 million. This brought its stake in Suzhou Hybiome Biomedical Engineering Co. Ltd from 92.6% at December 31, 2025 to 95.9% at June 30, 2026.

1.1.3 Comparable information on changes in the scope of consolidation

No comparable information is presented in the profit & loss statement, as the impact of the changes in the scope of consolidation was not material.

Where applicable, any impacts of changes in the scope of consolidation are shown on a separate line of the cash flow statement and tables showing any year-on-year changes in the explanatory notes.

1.2. SIGNIFICANT EVENTS OF THE FIRST HALF

1.2.1 Economic and geopolitical context

In the first half of 2026, the Group was still operating in an environment characterized by persistent macroeconomic and geopolitical uncertainty, particularly the crisis in the Middle East, which led to increased transportation costs.

As for tariffs in the U.S., following the decision of the Supreme Court of the United States on February 20, 2026, which found certain tariffs imposed in 2025 to be unconstitutional, bioMérieux has requested the refund of $16.8 million from the CBP (Customs and Border Protection). At June 30, 2026, the Group had received $15.2 million. The positive impact recorded under gross profit amounts to €13.0 million. At the same time, the tariff-related costs recorded in the first half of 2026 were more than €10 million higher than for the previous year, particularly due to the United States.

1.3. SUMMARY OF SIGNIFICANT EVENTS IN 2025

The significant events of the fiscal year 2025 were as follows:

- The acquisition of SpinChip Diagnostics ASA on January 20, 2025, for approximately €112 million. This subsidiary has been wholly owned by the Group since the takeover date.
- The acquisition of Neoprospecta on January 29, 2025, for approximately €8 million. This subsidiary has been wholly owned by the Group since the takeover date.
- The acquisition of the assets of Day Zero Diagnostics on June 13, 2025, for €19 million.
- The acquisition of an additional 5.2% stake in Suzhou Hybiome Biomedical Engineering Co. Ltd for approximately €1.5 million. The stake in this company rose from 87.4% at December 31, 2024, to 92.6% at December 31, 2025.
- An impairment loss on the VITEK® REVEAL™ technology for €145.5 million at the average rate for the first half of 2025 (and €140.7 million at the average rate for 2025 overall) was recorded in the financial statements at June 30, 2025, and December 31, 2025, respectively. This impairment was recorded under amortization and impairment of intangible assets related to acquisitions and acquisition-related costs.
- Announcement of the closure of the San José site in December 2025. Impairment losses on tangible and leased assets for €27.5 million and restructuring costs for €12.8 million were recognized on December 31, 2025.

- The employee share ownership plan, known as “MyShare,” impacted personnel costs by approximately €8 million in the first half of 2025.

The significant events of fiscal year 2025 did not have a material impact on the financial statements for the first half of 2026, with the exception of:

- the acquisition of SpinChip Diagnostics ASA, for which research and development work is underway to bring this solution to market in the near future;
- the reversal of previously provisioned restructuring costs for €4.9 million due to the early closure of the site and voluntary employee departures, recognized as other non-recurring income and expenses from operations related to the San José site (see Note 16.2).
- the new “MyShare” employee share ownership plan, representing a personnel cost of approximately €5 million, recorded under general and administrative expenses at June 30, 2026.

2. GENERAL ACCOUNTING PRINCIPLES

2.1. STANDARDS, AMENDMENTS AND INTERPRETATIONS

The condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS), including all standards, amendments and interpretations adopted by the European Commission at June 30, 2026. These standards, amendments and interpretations can be consulted on the European Commission’s website.

The condensed interim consolidated financial statements were prepared and are presented in accordance with IAS 34 “Interim Financial Reporting.” The notes to the interim financial statements are presented in condensed format.

Information provided in the notes relates only to material items, transactions and events whose disclosure provides for a better understanding of changes in the bioMérieux Group’s financial position and performance.

The accounting principles and calculation methods used to prepare the interim financial statements at June 30, 2026 and June 30, 2025 are identical to those used to prepare the consolidated financial statements at December 31, 2025 and described in detail in the Universal Registration Document filed with the AMF on March 16, 2026, with the exception of the standards, amendments and interpretations that came into force in 2026. In some cases, these rules have been adapted to the specific nature of interim financial statements, in accordance with IAS 34.

The new standards, amendments and interpretations adopted by the European Commission and effective from January 1, 2026 are presented below:

- amendments to IFRS 7 and IFRS 9, on the classification and measurement of financial instruments, adopted by the IASB in May 2024 and by the EU in May 2025;
- amendments to IFRS 7 and IFRS 9, on contracts for the purchase of electricity from natural sources, adopted by the IASB in December 2024, and adopted by the EU in June 2025;
- annual improvements to standards – Volume 11: amendments to IFRS 1, 7, 9, 10 and IAS 7, adopted by the IASB in July 2024, and adopted by the EU in July 2025.

These amendments had no significant impact on the Group’s financial statements at June 30, 2026.

The standards, amendments and interpretations adopted by the IASB that will enter into force for fiscal years beginning on or after January 1, 2027 and that were pending adoption or had been adopted by the EU at June 30, 2026, are as follows:

Effective as of January 1, 2027:

- IFRS 18, Presentation and Disclosure in Financial Statements, adopted by the IASB in April 2024, and adopted by the EU on February 16, 2026.

bioMérieux did not early adopt IFRS 18 in 2026. The Group is currently continuing its assessment work to evaluate the impact of this standard on the presentation of the consolidated financial statements and the related disclosures, pending further clarification on a number of key matters, particularly from the IFRS Interpretations Committee.

The changes introduced by IFRS 18 primarily involve the addition of mandatory subtotals in the profit & loss statement, new defined categories for income and expenses (operating, investing and financing), and new requirements for the performance measures defined by management.

The profit & loss statement will still be presented by function, with adjustments to certain items in accordance with the principle of providing a useful structured summary as defined by IFRS 18. Work is ongoing in this regard, pending further clarification from the IFRS Interpretations Committee in particular, regarding the potential use of additional subtotals and the presentation of a number of specific line items within operating income.

The Group does not anticipate any significant impact on the presentation of its consolidated balance sheet. Regarding the cash flow statement, the standard changes the starting point for the indirect method, which will now be based on operating income rather than net income. The impacts of this change are currently being analyzed and are not expected to be significant.

At this stage, the identified performance measures (MPM) include EBITDA, contributive operating income before non-recurring items and adjusted net earnings per share. These measures, which are currently used in the Group's financial communications and are reconciled with the IFRS profit & loss statement in Note 24 to the consolidated financial statements at June 30, 2026, will continue to be defined and reconciled in the notes to the financial statements, without any significant changes expected in their definition.

There are no standards, amendments and interpretations published by the IASB, with mandatory application for the fiscal years opened on January 1, 2026, but not yet approved at the European level (and for which early application is not possible on a European level), that would have had a material impact on the consolidated financial statements.

The financial statements of consolidated Group companies that are prepared in accordance with local accounting principles are restated to comply with the principles used for the consolidated financial statements.

2.2. JUDGMENTS AND ESTIMATES

Judgments and estimates did not change significantly compared to June 30, 2025, and December 31, 2025 (see Note 2.3 to the consolidated financial statements at December 31, 2025).

As noted in Note 1.2.1, no estimates of US tariffs were provided in the interim financial statements. The Group does not expect these tariff measures to have any significant impact on relationships with suppliers or customers.

There have been no significant changes to the impact of climate change on the financial statements, compared with the information given in Note 2.3 to the consolidated financial statements at December 31, 2025:

- Risks related to climate change effects, in relation to those currently assessed, as well as the Group's commitments in terms of carbon neutrality and the reduction of greenhouse gas emissions, did not have a significant impact on the financial statements.
- The import volumes subject to the carbon border adjustment mechanism (CBAM), both actual and projected for 2026, remain below the regulatory exemption threshold of 50 metric tons. As a result, no liabilities were recognized in the financial statements at June 30, 2026.

2.3. PRESENTATION OF THE PROFIT & LOSS STATEMENT

The Group uses contributive operating income before non-recurring items as a key performance indicator for financial reporting purposes (see Note 24 for details on the alternative performance indicators). It is not included in the published profit & loss statement.

Amortization and impairment of intangible assets related to acquisitions and acquisition-related costs are recorded on a separate line in the profit & loss statement. They are included in the published figure for operating income before non-recurring items but excluded from contributive operating income before non-recurring items.

The definition of other non-recurring income and expenses from operations is the same as that applied in previous years (see Note 24.1 to the 2025 consolidated financial statements).

2.4. SEASONALITY OF OPERATIONS

Given the importance of its respiratory panels, BioFire sales are significantly influenced by changes in the timing and intensity of respiratory diseases and seasonal influenza epidemics.

The sensitivity of the Group's other businesses to seasonal fluctuations is not material. Revenues and operating income before non-recurring items tend to be slightly higher in the second half of the year.

3. CHANGES IN INTANGIBLE ASSETS AND AMORTIZATION

3.1. ACCOUNTING PRINCIPLES

3.1.1 Impairment tests on non-current assets

For each year-end closing, the Group systematically performs impairment tests on goodwill and on other intangible assets with indefinite useful lives, as described in Note 4.2 to the consolidated financial statements at December 31, 2025. Similarly, other intangible assets and property, plant and equipment with finite useful lives undergo impairment tests whenever there is a sign of impairment losses, in accordance with the methods described in the aforementioned note.

For the interim financial statements, impairment tests are performed only for significant assets or groups of assets for which an impairment indicator exists at the end of the reporting period. The VITEK® REVEAL™ technology was tested for impairment, revealing no impairments during the first half of 2026. No other impairment indicators have been identified.

It should be noted that at June 30, 2025 and December 31, 2025, the impairment tests carried out in accordance with the rules outlined in Note 4.2 to the 2025 consolidated financial statements had led the Group to record an impairment loss of €145.5 million on the VITEK® REVEAL™ technology at the average rate for the first half of 2025 (or €140.7 million at the average rate for 2025 overall), which was reported under amortization and impairment of intangible assets related to acquisitions and acquisition-related costs.

3.2. CHANGES IN GOODWILL

In millions of euros	Net value
DECEMBER 31, 2024	**730.4**
Translation differences	-52.2
Changes in the scope of consolidation (a)	49.6
Impairment losses	0.0
DECEMBER 31, 2025	**727.8**
Translation differences	15.1
Changes in the scope of consolidation (b)	14.1
Impairment losses	0.0
JUNE 30, 2026	**757.1**

(a) Related to the acquisition of SpinChip Diagnostics ASA and Neoprospecta

(b) Related to the acquisition of Accellix

The change in scope during the period corresponded to the provisional goodwill arising from the acquisition of Accellix for €14.1 million (see Note 1.1.1).

At June 30, 2026, no indications of impairment were identified (see Note 3.1.1).

3.3. CHANGES IN OTHER INTANGIBLE ASSETS AND AMORTIZATION

Other intangible assets mainly comprise patents and technologies.

Gross value *In millions of euros*	**Patents Technology**		**Software**	**Other**	**Total**
DECEMBER 31, 2024	**1,019.6**		**263.6**	**35.9**	**1,319.1**
Translation differences	-97.2		-10.0	-2.1	-109.3
Acquisitions/Increases	0.7		5.8	2.6	9.1
Changes in the scope of consolidation	128.2	(a)	0.0	0.0	128.2
Disposals/Decreases	-13.6		-33.4	-0.2	-47.2
Reclassifications	0.0		4.7	-3.8	1.0
Hyperinflation	0.0		0.8	0.2	1.0
DECEMBER 31, 2025	**1,037.8**		**231.5**	**32.7**	**1,302.0**
Translation differences	27.9		2.8	0.6	31.3
Acquisitions/Increases	1.4		0.2	2.5	4.1
Changes in the scope of consolidation	24.4	(b)	0.0	0.0	24.4
Disposals/Decreases	0.0		-1.4	0.0	-1.4
Reclassifications	-0.3		1.8	-1.6	-0.2
Hyperinflation	0.0		0.6	0.1	0.7
JUNE 30, 2026	**1,091.1**		**235.5**	**34.3**	**1,361.0**

Amortization and impairment losses *In millions of euros*	**Patents Technology**		**Software**	**Other**	**Total**
DECEMBER 31, 2024	**581.0**		**229.0**	**17.1**	**827.1**
Translation differences	-54.5		-8.2	-1.0	-63.6
Additions	174.3	(c)	6.4	12.9	193.7
Changes in the scope of consolidation	0.0		0.0	0.0	0.0
Reversals/Disposals	-22.7	(d)	-33.4	-1.4	-57.5
Reclassifications	0.0		10.6	-10.6	0.0
Hyperinflation	0.0		0.7	0.2	0.9
DECEMBER 31, 2025	**678.1**		**205.1**	**17.3**	**900.5**
Translation differences	20.2		2.4	0.3	23.0
Additions	14.6		7.4	0.6	22.6
Changes in the scope of consolidation	0.3		0.0	0.0	0.3
Reversals/Disposals	0.0		-1.4	0.0	-1.4
Reclassifications	0.0		0.0	0.1	0.1
Hyperinflation	0.0		0.5	0.1	0.7
JUNE 30, 2026	**713.2**		**214.2**	**18.5**	**945.9**

Net value *In millions of euros*	**Patents Technology**	**Software**	**Other**	**Total**
DECEMBER 31, 2024	**438.6**	**34.7**	**18.8**	**492.0**
DECEMBER 31, 2025	**359.7**	**26.5**	**15.4**	**401.5**
JUNE 30, 2026	**377.9**	**21.3**	**15.8**	**415.1**

(a) Related to the acquisition of SpinChip Diagnostics ASA and Neoprospecta, as well as the assets of Day Zero Diagnostics
(b) Related to the acquisition of Accellix
(c) Includes the provision for impairment of the VITEK® REVEAL technology (see Note 3.1.1)
(d) Mainly related to a partial reversal of the impairment provision for Astute technology, valued at €9.4 million at the average rate for fiscal year 2025.

The changes in scope during the period essentially corresponded to the acquisition of the Accellix entities for €24.4 million (see Note 1.1.1).

4. CHANGES IN PROPERTY, PLANT AND EQUIPMENT, RIGHT-OF-USE ASSETS AND DEPRECIATION

4.1. CHANGES IN PROPERTY, PLANT AND EQUIPMENT

Gross value *In millions of euros*	**Land**	**Buildings**	**Machinery and equipment**	**Capitalized instruments**	**Other assets**	**Assets under construction**	**Total**
DECEMBER 31, 2024	**63.6**	**954.2**	**808.0**	**640.2**	**224.2**	**355.4**	**3,045.6**
Translation differences	-3.6	-64.3	-56.8	-28.6	-14.0	-27.5	**-194.9**
Changes in the scope of consolidation			2.2				**2.2**
Acquisitions/Increases	1.3	24.8	23.9	115.3	7.4	153.1	**325.9**
Disposals/Decreases	-0.2	-5.3	-35.2	-48.5	-9.7		**-98.9**
Reclassifications	1.9	80.4	130.4	0.3	3.6	-212.4	**4.1**
Hyperinflation		0.0	0.0	5.0	0.2	0.0	**5.2**
DECEMBER 31, 2025	**63.0**	**989.8**	**872.5**	**683.7**	**211.7**	**268.5**	**3,089.2**
Translation differences	1.0	21.5	18.4	11.2	3.7	4.3	**60.2**
Changes in the scope of consolidation		0.1	1.2	0.6	0.6		**2.5**
Acquisitions/Increases		1.1	3.4	53.0	3.3	56.4	**117.3**
Disposals/Decreases		-0.4	-4.6	-26.2	-1.6	-0.5	**-33.3**
Reclassifications	0.8	17.4	34.7	0.2	4.2	-55.9	**1.4**
Hyperinflation		0.0	0.0	4.5	0.2	0.0	**4.8**
JUNE 30, 2026	**64.9**	**1,029.7**	**925.6**	**727.0**	**222.1**	**272.9**	**3,242.1**

Depreciation and impairment losses *In millions of euros*	**Land**	**Buildings**	**Machinery and equipment**	**Capitalized instruments**	**Other assets**	**Assets under construction**	**Total**
DECEMBER 31, 2024	**3.9**	**481.6**	**495.7**	**344.5**	**170.7**	**23.8**	**1,520.2**
Translation differences	-0.2	-27.9	-31.3	-12.8	-10.5	-1.6	**-84.3**
Changes in the scope of consolidation			1.2				**1.2**
Additions	0.4	84.6	67.4	73.5	15.8	-24.2	**217.5**
Disposals/Decreases	-0.2	-4.8	-34.1	-42.1	-9.5		**-90.7**
Reclassifications		0.0	2.4	0.1	0.5	2.0	**5.0**
Hyperinflation		0.0	0.0	4.3	0.2		**4.6**
DECEMBER 31, 2025	**3.8**	**533.6**	**501.3**	**367.5**	**167.0**		**1,573.4**
Translation differences	0.1	10.3	9.1	5.5	2.8		**27.9**
Changes in the scope of consolidation		0.1	0.8	0.5	0.5		**2.0**
Additions	0.2	21.7	34.1	37.9	7.2		**101.1**
Disposals/Decreases		-0.4	-4.4	-23.4	-1.5		**-29.7**
Reclassifications			-0.4	0.0	0.4		**0.0**
Hyperinflation		0.0	0.0	3.5	0.2		**3.8**
JUNE 30, 2026	**4.1**	**565.4**	**540.5**	**391.6**	**176.6**		**1,678.4**

Net value *In millions of euros*	**Land**	**Buildings**	**Machinery and equipment**	**Capitalized instruments**	**Other assets**	**Assets under construction**	**Total**
DECEMBER 31, 2024	**59.7**	**472.6**	**312.3**	**295.7**	**53.6**	**331.6**	**1,525.4**
DECEMBER 31, 2025	**59.2**	**456.1**	**371.2**	**316.2**	**44.7**	**268.5**	**1,515.9**
JUNE 30, 2026	**60.7**	**464.2**	**385.0**	**335.4**	**45.5**	**272.9**	**1,563.8**

Assets under construction mainly relate to investments in production and automation tools in the United States and France.

4.2. RIGHT-OF-USE ASSETS

4.2.1 Accounting principles

The accounting principles for rental agreements are described in Note 6.2 to the 2025 consolidated financial statements.

The analysis did not identify any indications of impairment at June 30, 2026 on right-of-use assets.

No material changes were made to rental agreements in the first half of 2026.

4.2.2 Change

GROSS VALUE *In millions of euros*	**Land**	**Buildings**	**Machinery and equipment**	**Other assets**	**TOTAL**
DECEMBER 31, 2024	**26.8**	**198.4**	**47.2**	**4.6**	**276.9**
Translation differences	-2.8	-11.3	-2.8	0.0	**-16.9**
Changes in the scope of consolidation		3.6			**3.6**
Acquisitions/Increases	0.5	10.8	17.7	0.3	**29.2**
Disposals/Decreases		-28.0	-9.0	-0.2	**-37.3**
Reclassifications					
DECEMBER 31, 2025	**24.4**	**173.5**	**53.1**	**4.6**	**255.6**
Translation differences	0.7	2.7	0.8	0.0	**4.2**
Changes in the scope of consolidation		0.6			**0.6**
Acquisitions/Increases		10.2	8.4	0.3	**18.8**
Disposals/Decreases		-1.9	-5.2	-0.5	**-7.5**
Reclassifications		0.0			**0.0**
JUNE 30, 2026	**25.1**	**185.0**	**57.1**	**4.5**	**271.7**

DEPRECIATION *In millions of euros*	**Land**	**Buildings**	**Machinery and equipment**	**Other assets**	**TOTAL**
DECEMBER 31, 2024	**4.7**	**77.5**	**20.1**	**4.4**	**106.7**
Translation differences	-0.6	-3.3	-1.2	0.0	**-5.0**
Changes in the scope of consolidation					
Additions	0.5	25.5	12.2	0.2	**38.3**
Disposals/Decreases		-18.5	-7.0	-0.2	**-25.7**
Reclassifications					
DECEMBER 31, 2025	**4.6**	**81.2**	**24.1**	**4.4**	**114.4**
Translation differences	0.1	1.0	0.4	0.0	**1.5**
Changes in the scope of consolidation					
Additions	0.3	9.9	6.6	0.1	**16.9**
Disposals/Decreases		-1.2	-4.6	-0.5	**-6.2**
Reclassifications		0.0			**0.0**
JUNE 30, 2026	**5.0**	**91.0**	**26.6**	**4.0**	**126.5**

NET VALUE *In millions of euros*	Land	Buildings	Machinery and equipment	Other assets	TOTAL
DECEMBER 31, 2024	**22.1**	**120.9**	**27.1**	**0.1**	**170.2**
DECEMBER 31, 2025	**19.8**	**92.2**	**29.0**	**0.2**	**141.3**
JUNE 30, 2026	**20.1**	**94.0**	**30.6**	**0.4**	**145.1**

The increases are primarily linked to new leases. The decreases are primarily due to agreements reaching the end of their terms, as well as a review of the duration of certain real estate agreements.

The table below shows the assets held by the Group under leasing agreements:

NET VALUE *In millions of euros*	Land	Buildings	Machinery and equipment	Other assets	TOTAL
DECEMBER 31, 2024	**2.3**	**21.9**			**24.2**
DECEMBER 31, 2025	**2.3**	**19.5**			**21.8**
JUNE 30, 2026	**2.3**	**18.3**			**20.6**

5. CHANGES IN NON-CURRENT FINANCIAL ASSETS

In millions of euros	Acquisition value	Changes in fair value	Fair value
DECEMBER 31, 2024	**266.0**	**-71.0**	**195.0**
Translation differences	-5.8	1.5	-4.3
Acquisitions/Increases	7.8	0.0	7.8
Disposals/Decreases	-13.5	-16.9	-30.4
Changes in fair value recognized in other comprehensive income		-39.3	-39.3
DECEMBER 31, 2025	**254.5**	**-125.7**	**128.7**
Translation differences	1.6	-1.4	0.2
Acquisitions/Increases	1.1	0.0	1.1
Disposals/Decreases	-12.2	5.1	-7.1
Changes in fair value recognized in other comprehensive income		-1.8	-1.8
JUNE 30, 2026	**244.9**	**-123.8**	**121.1**

The decreases are primarily related to the conversion into equity of a loan held by Accellix as part of its acquisition (see Note 1.1.1).

The change in fair value recorded in other comprehensive income mainly concerns Oxford Nanopore Technologies (the valuation of which is based on the share price at June 30, 2026).

The value of the non-current financial assets was reviewed at June 30, 2026. The summary table below shows the change in fair value of shares in non-consolidated companies at June 30, 2026 compared to December 31, 2025.

	12/31/2025		06/30/2026	
In millions of euros	Fair value	Of which changes in fair value through other comprehensive income	Fair value	Of which changes in fair value through other comprehensive income
Oxford Nanopore Technologies	86.9	-4.8	85.1	-1.9
Proxim		-15.9		
Accunome		-12.3		
Other securities	26.4	-6.2	26.5	0.1
TOTAL	**113.3**	**-39.3**	**111.6**	**-1.8**

6. ASSETS AND LIABILITIES HELD FOR SALE

There were no assets or liabilities held for sale at June 30, 2026 or December 31, 2025.

7. INVENTORIES

At a constant exchange rate (the 2025 closing rate), inventories were down by approximately €8 million over the period.

In millions of euros	06/30/2026	12/31/2025
Raw materials	383.7	392.6
Work-in-progress	109.8	107.6
Finished products and goods held for resale	520.7	496.2
GROSS VALUE	**1,014.1**	**996.5**
Raw materials	-22.4	-19.1
Work-in-progress	-2.8	-2.6
Finished products and goods held for resale	-13.5	-15.1
PROVISIONS FOR IMPAIRMENTS	**-38.8**	**-36.8**
Raw materials	361.2	373.6
Work-in-progress	106.9	105.0
Finished products and goods held for resale	507.2	481.1
NET VALUE	**975.3**	**959.7**

Just like in 2025, the Group did not experience significant slowdowns over the manufacturing period of the inventories recognized at June 30, 2026.

8. TRADE RECEIVABLES AND ASSETS RELATED TO CONTRACTS WITH CUSTOMERS

In millions of euros	06/30/2026	12/31/2025
Trade receivables	751.7	801.9
Impairment	-36.4	-35.8
NET VALUE	**715.3**	**766.2**

There are no other assets related to contracts with customers.

Trade receivables include the current portion of leasing agreement receivables.

RECEIVABLES AND ASSETS RELATED TO CONTRACTS WITH CUSTOMERS	12/31/2025	Changes in the scope of consolidation	Changes in gross values	Changes in impairment	Currency impact	06/30/2026
Long-term leasing agreement receivables	10.3		0.6		0.3	11.2
NON-CURRENT ASSETS	**10.3**		**0.6**	**0.0**	**0.3**	**11.2**
Leasing agreement receivables	3.7		2.0	-0.2	0.2	5.7
Trade receivables	762.5	1.2	-65.4	0.3	11.2	709.6
CURRENT ASSETS	**766.2**	**1.2**	**-63.5**	**0.1**	**11.4**	**715.3**

The analysis carried out, in light of the economic and geopolitical context (see Note 1.2.1), did not result in any changes being made to the trade receivables provisioning model or implementation procedures in 2026.

9. LIABILITIES RELATED TO CONTRACTS WITH CUSTOMERS

Liabilities related to contracts with customers mainly correspond to advances received and maintenance services invoiced in advance on service contracts. These contracts have a term of one year. The associated revenue is recognized in profit and loss over the period that the service is rendered. In practice, the revenue from these contracts is recognized over the 12 months following their invoicing. No material adjustments were made to any liabilities related to contracts with customers during the first half of 2026.

LIABILITIES RELATED TO CONTRACTS WITH CUSTOMERS	12/31/2025	Changes in the scope of consolidation	Change in gross values	Change in impairment	Reclassifications	Changes in translation differences	06/30/2026
Impairment for long-term guarantee	1.1	0.0		0.1	0.0	0.0	1.2
NON-CURRENT LIABILITIES	**1.1**	**0.0**	**0.0**	**0.1**	**0.0**	**0.0**	**1.2**
Impairment for short-term guarantee	4.4			-0.6	0.0	0.1	3.9
Advances on contracts with customers	8.2		3.0		0.0	0.2	11.5
Credit notes to be issued	15.0		-3.0		0.0	0.2	12.2
Deferred revenue	77.9	0.2	7.8		1.0	1.8	88.7
CURRENT LIABILITIES	**105.5**	**0.2**	**7.9**	**-0.6**	**1.0**	**2.3**	**116.3**

10. SHAREHOLDERS' EQUITY AND EARNINGS PER SHARE

10.1. SHARE CAPITAL

The Company's share capital amounted to €12,029,370 at June 30, 2026 and was divided into 118,361,220 shares with a total of 194,173,387 voting rights (of which 75,812,167 shares carry double voting rights). Following a decision taken by the Annual General Meeting of March 19, 2001, the Company's articles of association no longer refer to a par value for its shares. Other than the free shares, there were no valid dilutive rights or securities at June 30, 2026.

Treasury shares held under the liquidity agreement

At June 30, 2026, the parent company held 116,177 treasury shares (compared with 35,173 at June 30, 2025, and 41,528 at December 31, 2025) in connection with a liquidity agreement entered into with a third party for market-making purposes. In the first six months of the fiscal year, the Company purchased 777,444 and sold 702,795 of its treasury shares under the liquidity agreement.

Other treasury shares

During the first half of 2026, the Company bought 350,000 shares and definitively allocated 128,582 shares in connection with the MyShare subscription plan. At June 30, 2026, the Company held 552,959 treasury shares, to partially cover performance-based free share plans.

The expense recorded for the first half of the 2026 in respect of employee free share payment plans totaled €7.3 million, excluding the expenses related to employers' contributions, corresponding to the accrued portion of the estimated liability recognized over the vesting period. This expense was €12.6 million in the first half of 2025.

The MyShare plan generated personnel costs of approximately €5 million in the financial statements for the first half of 2026 compared with €8 million the year before (see Note 1.3).

10.2. CUMULATIVE TRANSLATION ADJUSTMENTS

In millions of euros	06/30/2026	12/31/2025	06/30/2025
Dollar (a)	28.1	-58.0	-72.3
Latin America	-19.6	-27.4	-28.1
Europe – Middle East – Africa	-48.2	-43.9	-29.7
Other countries	-9.6	-16.9	-12.9
TOTAL	**-49.3**	**-146.3**	**-143.1**

(a) U.S. and Hong Kong dollars

Cumulative translation adjustments attributable to the parent company amounted to -€48.9 million at June 30, 2026, including +€31.1 million linked to hyperinflation compared with -€145.6 million at December 31, 2025. This increase is mainly due to the dollar's appreciation over the period.

10.3. EARNINGS PER SHARE

Basic earnings per share is calculated by dividing net income attributable to owners of the parent by the weighted average number of shares outstanding during the period (excluding shares intended for allocation to employees under free share grants and treasury shares held for market-making purposes and other share buyback programs).

Diluted (net) earnings per share are calculated using the number of shares defined in the basic earnings plus the weighted average number of potential shares to be issued that would have a dilutive effect on net income. The number of the latter was 118,367,848 at June 30, 2026, compared with 118,905,491 at June 30, 2025.

Adjusted diluted (net) earnings per share corresponds to the diluted (net) earnings per share adjusted to include amortization and impairment losses on intangible assets related to acquisitions (see Note 15) and other non-recurring income and expenses from operations (see Note 16). This is detailed in Note 24.

11. PROVISIONS – CONTINGENT ASSETS AND LIABILITIES

11.1. ACCOUNTING PRINCIPLES

11.1.1 Provisions

The recognition and measurement criteria for provisions are identical to those used at December 31, 2025 (see Note 15.1 to the consolidated financial statements at December 31, 2025).

Additions to and reversals of provisions are recognized in full based on the situation at June 30, 2026.

11.1.2 Post-employment benefits

In accordance with the amended IAS 19, the general principles applied are as follows:

Post-employment benefit obligations are presented in the balance sheet at their total amount less the fair value of plan assets. Benefit obligations and the fair value of plan assets are calculated in an identical way to the methods used at December 31, 2025 (see Note 15.3 to the consolidated financial statements at December 31, 2025).

Just like at June 30, 2025, in accordance with the provisions of IAS 34, post-employment benefit obligations and equivalent were not calculated in full at June 30, 2026.

Changes in net obligations were estimated as follows:

- Interest cost and service cost were estimated by extrapolating the total benefit obligation as calculated at December 31, 2025.
- The discount rates were updated at June 30, 2026, and the impact of their change was assessed at that date.
- The analysis carried out at June 30, 2026 did not result in any changes to the other actuarial assumptions related to the total benefit obligation (including the salary increase and turnover rates) compared to December 31, 2025.
- Other actuarial gains and losses related to experience adjustments were not recalculated due to their non-material impact during previous years and to the fact that no material changes are expected in the current fiscal year.
- Benefits paid to retired employees during the first half were recognized in full during the half-year.
- The Group updated the fair value of the plan assets at June 30, 2026. The expected return on plan assets was determined based on the discount rate used to measure post-employment benefit obligations.
- There were no changes made to the plan itself during the first half of 2026 in relation to post-employment benefit obligations and equivalent.
- Regarding long-service awards, the French social security financing law for 2026 abolished the tax and social-security exemption scheme applicable to long-service award bonuses in France. This change prompted the Group to remeasure the corresponding benefit obligations and record an additional expense of approximately €6 million in operating income at June 30, 2026.

Changes in the total net benefit obligation are set out in Note 11.3.

11.2. CHANGES IN PROVISIONS

In millions of euros	Retirement benefits and other benefits	Guarantees given	Restructuring	Claims and litigation	Other provisions	Total
DECEMBER 31, 2024	**41.0**	**10.6**	**0.3**	**4.2**	**30.4**	**86.5**
Additions	4.4	11.5	12.8	4.5	14.7	47.9
Reversals (utilizations)	-1.9	-9.3	0.0	-3.1	-4.5	-18.9
Reversals (surplus)	-0.2	-6.3	0.0	-0.7	-7.5	-14.7
Net additions (reversals)	2.4	-4.1	12.8	0.6	2.7	14.4
Actuarial gains and losses	-5.8	0.0	0.0	0.0	0.0	-5.8
Changes in the scope of consolidation	0.0	0.0	0.0	0.0	0.0	0.0
Other changes	0.0	0.0	-0.3	0.0	0.0	-0.2
Translation differences	-0.4	-0.9	-0.5	-0.1	-0.6	-2.5
DECEMBER 31, 2025	**37.2**	**5.6**	**12.4**	**4.8**	**32.5**	**92.3**
Additions	7.8	2.9	1.3	6.7	3.2	21.8
Reversals (utilizations)	-0.3	-3.0	-0.9	-2.4	-2.2	-8.8
Reversals (surplus)	-0.4	-0.4	-4.8	-0.1	-7.2	-13.0
Net additions (reversals)	7.1	-0.5	-4.5	4.2	-6.2	0.0
Actuarial gains and losses	-0.4	0.0	0.0	0.0	0.0	-0.4
Changes in the scope of consolidation	0.0	0.0	0.0	0.1	0.0	0.1
Other changes	0.1	0.0	0.0	6.3	0.0	6.4
Translation differences	0.0	0.1	0.3	0.3	0.3	1.0
JUNE 30, 2026	**44.0**	**5.1**	**8.2**	**15.7**	**26.6 (a)**	**99.5 (a)**

(a) See Note 11.5.

The total amount of provisions of €99.5 million includes current provisions for €46.0 million at June 30, 2026. Current provisions amounted to €44.3 million at December 31, 2025.

Net additions to provisions in the first half of 2026 represented €4.5 million in operating income before non-recurring items.

11.3. CHANGES IN POST-EMPLOYMENT BENEFITS AND OTHER EMPLOYEE BENEFITS

The net obligation at June 30, 2026 amounted to €43.6 million. This mainly comprised the provision for post-employment benefits (€20.7 million) and the provision for long-service awards (€22.9 million).

Post-employment benefits include plan assets in Switzerland that exceed the present value of obligations by €0.4 million.

Changes in the post-employment benefits obligation can be summarized as follows:

In millions of euros	Present value of obligation	Fair value of funds (a)	Provisions for pensions	Post-employment health insurance	Total provisions for post-employment benefits
DECEMBER 31, 2025	**69.1**	**-49.6**	**19.5**	**0.7**	**20.2**
Current service cost	2.0		2.0	0.0	2.0
Interest cost	1.2	-0.8	0.4	0.0	0.4
Retirements	-1.3	0.1	-1.2	0.0	-1.2
Plan liquidation	0.0	0.0	0.0		0.0
Contributions	0.0	-0.2	-0.2		-0.2
Impact on operating income	**2.0**	**-1.0**	**1.0**	**0.0**	**0.9**
Actuarial gains and losses (Other comprehensive income)	**-0.6**	**0.2**	**-0.4**	0.0	**-0.4**
Other movements (incl. currency impact)	0.1	-0.2	**-0.1**	0.0	**-0.1**
JUNE 30, 2026	**70.5**	**-50.5**	**20.0**	**0.7**	**20.7**

(a) Plan assets and scheduled payments

The discount rate for obligations in respect of eurozone countries is between 3.50% and 4.05% at June 30, 2026, depending on the duration of the plans. In France, the rates applied to post-employment benefits were largely unchanged compared to December 31, 2025, while those related to long-service award obligations decreased by approximately 35 basis points. The residual obligations in the United States are not material.

11.4. PROVISIONS FOR TAX DISPUTES, CLAIMS AND LITIGATION

As disclosed in Notes 15.4.1 and 15.4.2 to the consolidated financial statements 2025, the Group is involved in various tax disputes, claims, and provisions for tax disputes are presented together with current taxes payable, in accordance with IFRIC 23. The Company is also involved in a certain number of claims and litigations (related to trade, intellectual property and employees). The risks associated with these have been remeasured leading to an additional provision of approximately €6 million, which reflects the best estimate of the payments that may be required to address these risks.

11.5. Other provisions

Manovra Sanità

This law passed in August 2015 requires healthcare providers in Italy to cover 40% of the difference between the health budget of each province and the actual expenditure incurred.

In line with market practice, a provision for risk was recognized for the periods 2019 and 2022 to 2026 in an amount equal to 48% of total exposure pending the publication of an implementing decree. The Group considers the 2020 and 2021 fiscal years, which were impacted by the COVID-19 health crisis, to no longer pose a risk and it therefore reversed a provision of approximately €5 million during the first half of 2026.

Other provisions for contingencies and losses

These primarily relate to the employer contributions associated with free share plans, the risks associated with the discontinuation of certain products and the risks associated with equipment maintenance. These provisions were updated at June 30, 2026.

11.6. Contingent assets and liabilities

Diagnostic tests for Lyme disease

As stated in Note 15.5 to the consolidated financial statements at December 31, 2025, on October 14, 2016, bioMérieux, like other laboratories, was summoned before the Tribunal de Grande Instance de Paris by plaintiffs seeking compensation for anxiety allegedly "generated by the unreliability of serodiagnostic tests" for Lyme disease. The civil proceedings, initiated by 45 plaintiffs, increased to 93 following the joinder of two identical new summonses. In December 2021, the Paris court dismissed all opposing claims. The Paris court decision was the subject of an appeal brought by 30 claimants, notified to bioMérieux. The hearing before the Paris Court of Appeal took place on October 16, 2025. bioMérieux is awaiting the court's deliberation.

At this stage of the proceedings, it is impossible to reliably estimate the risk facing the Group.

12. NET DEBT – NET CASH AND CASH EQUIVALENTS

12.1. Consolidated cash flow statement

The cash flow statement separately lists:

- net cash from operating activities;
- net cash from investing activities;
- net cash from financing activities.

Net cash from investing activities includes the amount of net cash of companies acquired or sold on the date of their first-time consolidation or their derecognition, as well as amounts due to suppliers of non-current assets and amounts receivable on disposals of non-current assets.

Net cash and cash equivalents correspond to the Group's net debit and credit cash positions.

The consolidated cash flow statement shows the Group's EBITDA. EBITDA is not defined under IFRS and may be calculated differently by different companies. EBITDA or gross operating income as presented by bioMérieux is equal to the sum of operating income and net additions to operating depreciation and amortization.

In millions of euros	**2026 (6 months)**	**2025 (6 months)**
Additive method		
• Net income	225.8	160.6
• Cost of net financial debt	-1.0	-9.7
• Other financial income and expenses	6.1	5.7
• Income tax expense	68.8	52.6
• Net additions to amortization and impairment of intangible assets related to acquisitions	140.7	286.0
EBITDA	**440.3**	**495.1**
Simplified additive method		
• Operating income	299.7	209.2
• Operational depreciation and amortization	127.8	123.9
• Amortization and impairment of intangible assets related to acquisitions	12.8	162.0
EBITDA	**440.3**	**495.1**

The available free cash flow is a key indicator for the Group and is included in the cash flow statement. It is defined as cash flows from operating activities plus cash flows from investing activities, excluding net cash and cash equivalents from acquisitions and disposals of subsidiaries.

12.2. Comments on the cash flow statement

Net cash from operating activities

EBITDA came to €440.3 million in first-half 2026, or 22.4% of revenue, down 11.1% on the €495.1 million reported for the same period in 2025. This decrease is primarily due to a decrease in gross profit.

In the first half of 2026, the operating working capital requirement increased by €19.4 million, compared with a decrease of €74.8 million at June 30, 2025. The change was primarily a result of the following items:

- trade receivables fell by €63.4 million, primarily due to changes in business activities and the substantial collection of such receivables in the United States during the first half of 2026;
- inventories fell by €7.2 million in 2026 (or €8 million excluding currency impact) due to changes in inventories of raw materials;
- trade payables were down by €9.6 million mainly due to seasonality;
- other working capital requirement items decreased by €41.5 million, mainly taking account of the payment of 2025 annual variable compensation.

Income tax paid was €28.1 million, compared with €123.2 million at June 30, 2025. The significant decrease is the result of 2025 tax reforms in the United States, particularly the tax deduction for research and development expenses that were previously capitalized.

During the first half of 2026, net cash from operating activities amounted to €436.8 million, up 36.5% compared to the €320.1 million recorded during the previous period.

Net cash from investing activities

Disbursements on purchases of property, plant and equipment and intangible assets represented around 7.1% of revenues, i.e., €139.5 million in the first half of 2026, compared with €152.7 million in the first half of the prior fiscal year.

Increases in right-of-use assets are not shown within investing cash flows, in accordance with IFRS 16.

Accordingly, free cash flow amounted to €299.0 million at June 30, 2026, compared with €170.1 million at June 30, 2025.

On January 22, 2026, bioMérieux acquired 100% of Accellix Inc. and 100% of Accellix Ltd. This acquisition for €28.7 million resulted in a cash outflow of €27.8 million net of cash acquired.

As a reminder, the investing activities in the first half of 2025 were as follows:

- on January 20, 2025, bioMérieux acquired 100% of SpinChip Diagnostics ASA for €112.3 million net of cash acquired;
- on January 29, 2025, bioMérieux acquired 100% of Neoprospecta for €8 million, of which €2 million will be spread over a five-year-period, net of cash acquired;
- on June 13, 2025, bioMérieux acquired the assets of Day Zero Diagnostics for €19.2 million.

Net cash used in financing activities

At June 30, 2026, the Group paid out €115.2 million in dividends to bioMérieux SA shareholders, compared with €106.1 million in 2025.

The cash flows from loan repayments primarily consist of changes in commercial paper (-€16 million), loan repayments (-€30.2 million) and the repayment of debt related to IFRS 16.

12.3. CHANGES IN DEBT

At June 30, 2026, after the €115.2 million dividend payout to bioMérieux SA shareholders, the Group's net cash surplus was €235.9 million, largely consisting of net cash of €654.9 million offset by the bond issue described below, the debt on IFRS 16 lease liabilities and available cash (see Note 12.4).

In June 2020, bioMérieux conducted a bond issue of €200 million, comprising €145 million repayable in 2027 with an annual coupon of 1.50% and €55 million repayable in 2030 with an annual coupon of 1.902%. The first tranche of €145 million, which matures on June 29, 2027, is classified as current borrowings at June 30, 2026.

This bond issue is shown on the balance sheet at amortized cost calculated using the effective interest rate method including costs of issue, for a total of €199.9 million, €144.9 million of which is reported as a current bond issue.

At June 30, 2026, bioMérieux SA also had an undrawn syndicated credit facility of €600 million that matures in March 2028 (five years) with options to extend for two additional years. Following the exercise of extension options in February 2024 and February 2025, its maturity was extended to March 2030. On February 12, 2024, bioMérieux amended this syndicated credit facility agreement to include a margin adjustment mechanism based on the achievement of four Environmental, Social and Governance indicators. In 2025, the margin was not adjusted based on the achievement of these four indicators.

12.4. MATURITY OF NET DEBT

The maturity schedule presents net debt or net cash. This non-standardized measure corresponds to the sum of cash and cash equivalents with a maturity of less than three months, less committed debt and bank overdrafts and other uncommitted borrowings.

The maturity schedule below refers to balance sheet amounts.

In millions of euros	12/31/2025	Net cash acquired related to changes in scope	Disbursement related to acquisitions	Increase	Decrease	Change to the consolidated cash flow statement	Other movements (e)	Trans-lation differences	06/30/2026	
BORROWINGS – NON-CURRENT PORTION										
Borrowings – non-current portion	11.4			0.0	-0.9	-0.9	0.0	0.8	11.2	(f)
Non-current rental agreement liabilities	118.7					0.0	0.9	2.8	122.4	
Bond issues	199.9					0.0	-144.9		55.0	
TOTAL BORROWINGS – NON-CURRENT	**330.0**	**0.0**	**0.0**	**0.0**	**-0.9**	**-0.9**	**-144.0**	**3.5**	**188.6**	
BORROWINGS – CURRENT PORTION										
Current bond issue	0.0					0.0	144.9		144.9	
Borrowings due within one year	78.6			0.6	-30.2	-29.6	0.0	4.0	52.9	
Current rental agreement liabilities	32.1				-17.5	-17.5	17.3	0.5	32.4	
Commercial paper	16.0				-16.0	-16.0			0.0	
TOTAL BORROWINGS – CURRENT PORTION	**126.7**	**0.0**	**0.0**	**0.6**	**-63.7**	**-63.1**	**162.2**	**4.5**	**230.3**	**(g)**

TOTAL BORROWINGS (B)	**456.7**	**0.0**		**0.0**		**0.6**	**-64.6**	**-64.0**	**18.2**	**8.1**		**418.9**	
NET CASH AND CASH EQUIVALENTS													
Cash	257.7	0.9	(a)	-28.7	(b)	3.6		-24.2		3.0		236.5	
Cash investments	249.2					131.0		131.0		-0.1		380.2	
Cash investments with Institut Mérieux	62.9					-21.7		-21.7		0.0		41.2	
Cash and cash equivalents	**569.8**	**0.9**		**-28.7**		**112.8**	**0.0**	**85.0**	**0.0**	**2.9**		**657.8**	**(h)**
Bank overdrafts (c)	**-4.7**					**-13.1**		**-13.1**		**15.0**	**(d)**	**-2.9**	**(g)**
NET CASH (A)	**565.1**	**0.9**		**-28.7**		**99.7**	**0.0**	**71.9**	**0.0**	**17.9**		**654.9**	
NET DEBT (B) - (A)	**-108.4**	**-0.9**		**28.7**		**-99.0**	**-64.6**	**-135.9**	**18.2**	**-9.8**		**-235.9**	

(a) and (b) *Related to the acquisition of Accellix.*

(c) *Cash and bank overdrafts are repayable on demand, within the meaning of IAS 7.*

(d) *This amount includes cash pool-related effects.*

(e) *Other changes are related to new rental agreements not presented in financing flows in accordance with the standard.*

(f) *Including €2.2 million related to the acquisition of Neoprospecta, debt spread over a five-year period ending in 2030.*

(g) *Short-term borrowings on the consolidated balance sheet amounted to €233.2 million at June 30, 2026 and consisted of €230.3 million in current financial debts and €2.9 million in current bank loans.*

(h) *See Note 12.*

At June 30, 2026, non-current borrowings mainly comprised the bond issue conducted in 2020 for €55.0 million and lease liabilities (see Note 12.5 below).

The portion of borrowings due within one year mainly includes:

- the portion of the Euro PP loan due within one year, for which the first tranche of €144.9 million will mature on June 29, 2027;
- the loan taken out by bioMérieux Shanghai corresponding to a €40 million revolving credit facility;
- the loan taken out by Hybiome for €4 million;
- the portion of lease liabilities due within one year (see Note 12.5 below).

At the closing date, the Group had met all of its scheduled repayments.

No loan agreement was signed prior to June 30, 2026 concerning loans to be set up in the second half of 2026.

12.5. Impact of rental agreement liabilities on borrowings and financial debt

In millions of euros	**06/30/2026**	**12/31/2025**
Debt related to rental agreements	**154.9**	**150.9**
Of which rental agreements with purchase option	*7.7*	*10.5*
Due beyond 5 years	**45.4**	**46.4**
Of which rental agreements with purchase option	*0.0*	*0.0*
Due in 1 to 5 years	**77.0**	**72.3**
Of which rental agreements with purchase option	*3.8*	*6.7*
Due within 1 year	**32.4**	**32.1**
Of which rental agreements with purchase option	*3.8*	*3.8*

12.6. Borrowings covenants

In the event of a change in the effective control of the Company, holders of the Euro PP notes are entitled to request the redemption of their bonds.

The undrawn syndicated credit facility and the private placement bond subscribed in June 2020 are subject to a single covenant: “net debt to operating income before non-recurring items before depreciation and amortization and acquisition-related costs” calculated before the impact of applying IFRS 16. The ratio, which may not exceed 3.5, was complied with at June 30, 2026.

In March 2023, bioMérieux SA negotiated a new syndicated credit facility, taking the amount to €600 million. The facility is repayable in full at its term in 2028. Following the exercise of extension options, this maturity has been deferred to 2030.

Other term borrowings at June 30, 2026 mainly include short-term local financing and liabilities relating to fixed asset rental agreements. None of these borrowings are subject to covenants.

12.7. Interest rates

Before hedging, 83% of the Group’s borrowings are at fixed rates (€347.1 million), with the remainder at floating rates (€71.8 million).

The Group’s fixed-rate debt comprises:

- lease liabilities (€147.2 million) at a rate that mostly corresponds to the incremental borrowing rate (see Note 20.1);
- the private placement bond issued in June 2020 for €199.9 million.

Floating-rate borrowings are essentially based on the currency’s interest rate plus a margin.

12.8. Loan guarantees

None of the Group’s assets have been pledged as collateral to a bank.

bioMérieux may be required to issue a first call guarantee to banks granting external funding facilities to subsidiaries.

The Group’s hedging agreements are presented in Note 20.1.

13. REVENUE

Revenue is recognized in accordance with IFRS 15 “Revenue from Contracts with Customers.”

The revenue recognition criteria are identical to those used at December 31, 2025 (see Note 3.1 to the consolidated financial statements at December 31, 2025).

The table below presents the breakdown of revenue based on the different revenue categories, in accordance with IFRS 15.

In millions of euros	2026 (6 months)	2025 (6 months)
Sales of equipment	115.3	135.3
Sales of reagents	1,636.1	1,713.6
Sales of services	134.5	125.7
Equipment rentals [(a)]	38.1	29.6
Other revenue	40.5	39.5
Revenue	**1,964.6**	**2,043.8**

(a) Equipment rentals includes rent and the share of revenue from the sale of reagents that is reclassified as rent.

A breakdown by geographic area is provided in Note 19.3 on segment information. A breakdown by technology and application is provided in Note 19.4.

Analysis of IFRS 15 did not result in the identification of other revenue breakdown criteria.

14. OTHER OPERATING INCOME AND EXPENSES

Other income related to customer contracts mainly corresponds to royalties received.

In millions of euros	2026 (6 months)	2025 (6 months)
Net royalties received	1.1	1.5
Research tax credits	11.5	12.9
Research grants	0.0	0.4
Other	4.3	8.5
TOTAL	**16.9**	**23.2**

Other income mainly includes an insurance claim payment, rent in Durham (United States) for €2.6 million and a subsidy received in the United States.

Just like in previous fiscal years and financial reporting periods, in accordance with IAS 20, bioMérieux presents research tax credits as a subsidy within other operating income.

15. AMORTIZATION AND IMPAIRMENT OF INTANGIBLE ASSETS RELATED TO ACQUISITIONS AND ACQUISITION-RELATED COSTS

Amortization and impairment of intangible assets related to acquisitions and acquisition-related costs are recorded on a separate line in the profit & loss statement. They are included within operating income (see Note 2.3).

In millions of euros	2026 (6 months)	2025 (6 months)
Amortization of intangible assets	12.8	16.5
Impairment of intangible assets	0.0	145.5
Acquisition-related costs	1.4	1.2
TOTAL	**14.2**	**163.2**

At June 30, 2026, amortization and impairment of intangible assets related to acquisitions and acquisition-related costs amounted to €14.2 million, down by €149.0 million compared to June 30, 2025, due to the impairment of the VITEK® REVEAL™ technology the year before (see Note 1.3).

16. OTHER NON-RECURRING INCOME AND EXPENSES FROM OPERATIONS

16.1. ACCOUNTING PRINCIPLES

The other non-recurring income and expenses from operations for the period (such as restructuring costs) were recognized in full at June 30, 2026, rather than spread over the period. The recognition criteria are identical to those used at December 31, 2025 (see Note 24.1 to the consolidated financial statements at December 31, 2025).

16.2. CHANGES IN OTHER NON-RECURRING INCOME AND EXPENSES FROM OPERATIONS

Other non-recurring income and expenses from operations amounted to €0.6 million at June 30, 2026. These mainly comprise reversals of provisions related to the restructuring of the San José site, following a review of the assumptions related to termination benefits and early departures (see Note 1.3). This reversal was partially offset by new restructuring costs.

17. NET FINANCIAL EXPENSE

17.1. ACCOUNTING PRINCIPLES

Financial income and expenses are shown on two separate lines:

- "Cost of net financial debt," which includes interest expense, fees and foreign exchange gains and losses arising on borrowings, as well as income generated by cash and cash equivalents.
- "Other financial income and expenses," which includes interest income on instruments sold under lease, the impact of disposals and impairment of investments in non-consolidated companies, late payment interest charged to customers, discounting gains and losses, exchange rate gains and losses related to hyperinflation, and the ineffective portion of currency hedges on commercial transactions.

17.2. COST OF NET FINANCIAL DEBT

In millions of euros	2026 (6 months)	2025 (6 months)
Financial expenses on borrowings	-4.5	-4.1
Investment income	7.6	7.2
Currency hedging derivatives	2.3	-3.1
Foreign exchange gains and losses	-1.2	13.1
Interest on leasing debt	-3.2	-3.3
TOTAL COST OF DEBT	**1.0**	**9.7**

Financial expenses mainly comprise interest related to the bond issue and interest on local financing.

The change in foreign exchange gains and losses is due to the depreciation of the euro, which primarily occurred in dollar-denominated cash positions in 2026 (as opposed to the appreciation of the euro that primarily occurred in dollar-denominated cash positions in 2025).

17.3. OTHER FINANCIAL INCOME AND EXPENSES

In millions of euros	2026 (6 months)	2025 (6 months)
Interest income on leased assets	0.3	0.5
Impairment and disposal of non-current financial assets	0.0	0.0
Currency hedging derivatives (a)	-3.7	-5.0
Hyperinflation	-3.2	-1.7
Other	0.6	0.4
TOTAL OTHER FINANCIAL INCOME AND EXPENSES	**-6.1**	**-5.7**

(a) Corresponds to the impact of premiums/discounts on forward sales and to the effect of the time value of currency options, which the Group has elected not to treat as hedging costs.

Currency hedging derivatives mainly correspond to the ineffective portion on commercial transactions.

18. INCOME TAX

18.1. ACCOUNTING PRINCIPLES

The income tax expense for the first half is calculated individually for each entity by applying the estimated average tax rate for the fiscal year to the income before tax for the period.

The CVAE (*Cotisation sur la Valeur Ajoutée des Entreprises* – corporate value-added tax) is presented in operating income before non-recurring items.

The CIR (*Crédit Impôt Recherche* – research tax credit) was treated as a subsidy in accordance with IAS 20 (see Note 14) and presented in other operating income in the profit & loss statement. It was estimated at June 30, 2026, based on the underlying expenses incurred.

Deferred tax is recognized taking into account statutory changes in tax rates, particularly in France. There were no material changes during the first half of 2026.

18.2. CHANGES IN INCOME TAX

In millions of euros	2026 6 months Tax	2026 6 months Rate	2025 6 months Tax	2025 6 months Rate
Theoretical tax at standard French tax rate	**76.1**	**25.8%**	**55.1**	**25.8%**
- Impact of income tax at reduced tax rates and foreign tax rates	-4.0	-1.4%	-2.9	-1.4%
- Impact of FDII in the United States	-7.7	-2.6%	-4.5	-2.1%
- Impact of research tax credits presented in operating income	-2.6	-0.9%	-3.0	-1.4%
- Utilization of previously unrecognized tax assets	-1.0	-0.3%	-0.2	-0.1%
- Tax credits (other than research tax credits)	-1.5	-0.5%	-1.7	-0.8%
- Deferred tax assets not recognized on losses	1.2	0.4%	3.0	1.4%
- Recurring permanent differences	3.4	1.2%	1.3	0.6%
- Dividend tax	4.7	1.6%	4.3	2.0%
Actual income tax expense, excluding non-recurring effects	**68.7**	**23.3%**	**51.4**	**24.1%**
- Other non-recurring permanent differences	0.1	0.0%	1.2	0.5%
Actual income tax expense	**68.8**	**23.4%**	**52.6**	**24.7%**

The effective tax rate stood at 23.4% of income before tax, compared with 24.7% at June 30, 2025.

In 2026, the Group's effective tax rate continued to benefit from the Foreign-Derived Intangible Income (FDII) deduction in the United States, which represented a tax saving of €7.7 million at June 30, 2026 compared with €4.5 million at June 30, 2025.

As indicated in Note 2.1, the analyses carried out in connection with the application of the European Pillar Two Directive did not lead to the recognition of any additional expenses at June 30, 2026 (just like at June 30, 2025).

19. INFORMATION BY GEOGRAPHIC AREA, TECHNOLOGY AND APPLICATION

19.1. ACCOUNTING PRINCIPLES

Pursuant to IFRS 8 "Operating Segments," the Group has identified two operating segments within *in vitro* diagnostics.

In accordance with IFRS 8, information on revenue and assets broken down by geographic area is disclosed in Note 19.2, which has been prepared using the same accounting principles as those applied to prepare the annual consolidated financial statements.

19.2. INFORMATION BY BUSINESS SEGMENT

2026 (6 months) *In millions of euros*	**Clinical applications**	**Industrial applications**	**Other**	**Group**
Revenue	**1,634.1**	**330.4**	**0.0**	**1,964.6**
Cost of sales	-717.5	-147.1	-1.8	-866.4
Gross profit	**916.6**	**183.3**	**-1.8**	**1,098.2**
Other operating income and expenses	13.3	1.6	2.1	16.9
Selling and marketing expenses	-311.0	-82.7	3.3	-390.3
General and administrative expenses	-129.6	-26.3	1.9	-154.0
Research and development	-214.0	-32.0	-11.5	-257.4
Amortization and impairment of intangible assets related to acquisitions and acquisition-related costs	-10.6	-3.6	0.0	-14.2
OPERATING INCOME BEFORE NON-RECURRING ITEMS	**264.8**	**40.4**	**-6.0**	**299.1**
as % of revenue	*16%*	*12%*		

2025 (6 months) *In millions of euros*	**Clinical applications**	**Industrial applications**	**Other**	**Group**
Revenue	**1,724.4**	**319.4**	**0.0**	**2,043.8**
Gross profit	**999.4**	**175.9**	**-8.4**	**1,166.9**
Other operating income and expenses	16.0	1.3	6.2	23.5
Selling and marketing expenses	-328.9	-80.6	1.4	-408.0
General and administrative expenses	-136.7	-25.2	0.6	-161.3
Research and development	-211.4	-32.5	-5.5	-249.5
Amortization and impairment of intangible assets related to acquisitions and acquisition-related costs	-161.6	-1.6	0.2	-163.0
OPERATING INCOME BEFORE NON-RECURRING ITEMS	**176.8**	**37.4**	**-5.5**	**208.7**
as % of revenue	*10% (a)*	*12%*		

(a) Restated for impairment of the VITEK® REVEAL™ technology, operating income before non-recurring items as a percentage of revenue would be 19%.

19.3. INFORMATION BY GEOGRAPHIC AREA

The information by geographic area shown in the tables below has been prepared in accordance with the accounting principles used to prepare the consolidated financial statements.

2026 (6 months) *In millions of euros*	Americas		EMEA		Aspac	Corporate	Group
Revenue	**1,030.3**	(a)	**646.3**	(b)	**288.5**	**-0.5**	**1,964.6**
Cost of sales	-306.2		-271.7		-173.5	-115.0	-866.4
Gross profit	**724.1**		**374.6**		**114.9**	**-115.4**	**1,098.2**
as % of revenue	*70%*		*58%*		*40%*		
Other operating income and expenses	-170.3		-92.3		-53.6	-482.8	-799.1
OPERATING INCOME BEFORE NON-RECURRING ITEMS	**553.8**		**282.3**		**61.3**	**-598.2**	**299.1**
as % of revenue	*54%*		*44%*		*21%*		

(a) of which U.S. revenue: €855.8 million.

(b) of which France revenue: €114.2 million.

2025 (6 months) *In millions of euros*	Americas		EMEA		Aspac	Corporate	Group
Revenue	**1,085.6**	(a)	**636.9**	(b)	**317.0**	**4.3**	**2,043.8**
Cost of sales	-333.2		-275.7		-168.0	-100.0	-876.9
Gross profit	**752.4**		**361.2**		**149.1**	**-95.7**	**1,166.9**
as % of revenue	*69%*		*57%*		*47%*		
Other operating income and expenses	-181.3		-96.0		-45.4	-635.6	-958.3
OPERATING INCOME BEFORE NON-RECURRING ITEMS	**571.1**		**265.2**		**103.7**	**-731.4**	**208.7**
as % of revenue	*53%*		*42%*		*33%*		

(a) of which U.S. revenue: €926.3 million.

(b) of which France revenue: €118.1 million.

JUNE 30, 2026 *In millions of euros*	**Americas [(a)]**	**EMEA [(b)]**	**Aspac**	**Corporate**	**Group**
NON-CURRENT ASSETS					
Goodwill				757.1	**757.1**
Other intangible assets	10.5	10.6	0.2	393.7	**415.1**
Property, plant and equipment	762.7	577.5	36.6	186.9	**1,563.8**
Right-of-use assets	72.9	59.5	12.8		**145.1**
WORKING CAPITAL REQUIREMENT					
Inventories and work-in-progress	585.0	286.0	104.3		**975.3**
Trade receivables and assets related to contracts with customers	303.7	323.8	87.8		**715.3**
Trade payables	-115.9	-112.7	-23.5		**-252.1**

(a) Of which non-current assets in the United States: €775.9 million.

(b) Of which non-current assets in France: €454.8 million.

JUNE 30, 2025 *In millions of euros*	**Americas [(a)]**	**EMEA [(b)]**	**Aspac**	**Corporate**	**Group**
NON-CURRENT ASSETS					
Goodwill				727.6	**727.6**
Other intangible assets	13.8	16.7	0.3	380.5	**411.4**
Property, plant and equipment	728.6	496.9	43.4	174.0	**1,442.9**
Right-of-use assets	81.5	56.5	11.7		**149.7**
WORKING CAPITAL REQUIREMENT					
Inventories and work-in-progress	580.7	293.1	100.1		**973.9**
Trade receivables and assets related to contracts with customers	283.7	314.9	89.8		**688.4**
Trade payables	-90.6	-116.2	-22.1		**-228.9**

(a) Of which non-current assets in the United States: €772.1 million.

(b) Of which non-current assets in France: €397.3 million.

Regional data include commercial activities, corresponding mainly to revenue in each of the above geographic areas, the related cost of sales, and the operating expenses necessary for these commercial activities. Regional data also include costs not eligible for inclusion in the calculation of the cost price (e.g., project costs) of production sites located in those areas.

Corporate data mainly include the research and development costs incurred by the Clinic and Industry units, as well as the costs incurred by the Group’s corporate functions.

The revenue from research and development partnership agreements for companion tests is presented as unit revenue under Corporate.

19.4. Information by technology and application

The table below provides a breakdown of revenue by technology:

In millions of euros	2026 (6 months)	2025 (6 months)
Clinical applications	**1,634.1**	**1,724.4**
Molecular biology	809.1	902.7
Microbiology	652.8	646.6
Immunoassays	139.4	149.3
Other ranges	32.9	25.9
Industrial applications	**330.4**	**319.4**
TOTAL	**1,964.6**	**2,043.8**

20. EXCHANGE RATE AND INTEREST RATE RISK MANAGEMENT

Exchange rate, credit and interest rate risks are respectively described in Notes 28.1, 28.2 and 28.4 to the consolidated financial statements at December 31, 2025.

20.1. Hedging instruments

Currency hedges in effect at June 30, 2026, set up under the currency hedging policy described in Note 28.1.1 to the consolidated financial statements at December 31, 2025, are the following:

Currency hedges at June 30, 2026 *In millions of euros*	Maturities		2026 market value (a)
	< 1 year	1–5 years	
Hedges of existing commercial transactions			
• currency forward contracts	293.3	0.0	-1.8
• options	1.7	0.0	0.0
TOTAL	**295.0**	**0.0**	**-1.8**
Hedges of future commercial transactions			
• currency forward contracts	295.6	0.0	-1.1
• options	0.0	0.0	0.0
TOTAL	**295.6**	**0.0**	**-1.1**
Derivatives not qualifying as hedges	**0.0**	**0.0**	**0.0**
TOTAL	**0.0**	**0.0**	**0.0**

(a) Difference between the hedging rate at June 30, 2026 and the market rate at June 30, 2026, including premiums paid/received

All of the currency forward purchases and sales and options outstanding at June 30, 2026 had maturities of less than 12 months.

The analysis carried out at June 30, 2026 did not result in any changes to the qualification of the currency derivatives as hedges.

The table below summarizes hedging instruments held by the Group, and their changes in fair value:

			Fair value of the hedging instrument at closing		**Change in the fair value of the hedging instrument over the fiscal year**	
In millions of euros	**Type of hedge**	**Notional hedge amount at closing**	assets	liabilities	of which portion recognized as net income	of which portion recognized in other comprehensive income
FAIR VALUE HEDGES						
EUR interest rate risk						
Debt in EUR	interest rate swaps	-	-	-		
Debt in EUR	interest rate options	-	-	-		
Exchange rate risk					1.3	- 1.3
trade receivables in foreign currencies	forward sales	293.3	-	1.8		
trade debts in foreign currencies	forward purchases					
trade receivables in foreign currencies	options	1.7	-	0.0		
financial receivables in foreign currencies	forward sales	115.0	-	0.4		
borrowings in foreign currencies	forward purchases	325.4	1.4			
CASH FLOW HEDGES						
EUR interest rate risk						
Debt in EUR	interest rate swaps	-	-	-		
USD interest rate risk						
loan in $	cross currency swaps	-	-	-		
Exchange rate risk						
future commercial sales in foreign currencies	forward sales	295.6	-	1.1		
future commercial purchases in foreign currencies	forward purchases					
future commercial sales in foreign currencies	options	-	-	-		
DERIVATIVES NOT QUALIFYING AS HEDGES						
	forward sales	-		-		

The Group does not hold any instruments that fall under the category of net investment hedges.

20.2. LIQUIDITY RISK

Financial liabilities due in less than one year and in more than one year are classified in the balance sheet as current and non-current liabilities, respectively.

The Group is not exposed to liquidity risk on its current financial assets and liabilities since its total current financial assets far exceed its total current financial liabilities.

Accordingly, only the maturity schedule concerning net debt is presented (see Note 12.4).

The table below shows the projected cash flows from the private placement (divided into two tranches), the property lease agreement and contractual interest payments at June 30, 2026:

In millions of euros	Due within 1 year	Due in 1 to 5 years	Due beyond 5 years
EuroPP 7 years (a)	147.2	0.0	0.0
EuroPP 10 years (b)	1.0	58.1	0.0
Rental agreement with purchase option (incl. VAT) (c)	4.8	5.9	0.0
Shanghai revolving credit facility	40.8	0.0	0.0
Hybiome loan	4.3	0.0	0.0

(a) *Of which a* nominal amount of €145 million redeemable in less than one year

(b) *Of which a nominal amount of €55 million redeemable in more than one year*

(c) *Of which a nominal amount of €3.8 million redeemable in less than one year and €3.8 million redeemable in more than one year*

20.3. FINANCIAL INSTRUMENTS: FINANCIAL ASSETS AND LIABILITIES

A breakdown of financial assets and liabilities according to the categories specified by IFRS 9, including the "off-ledger" categories (see Note 27.1 to the consolidated financial statements at December 31, 2025), together with a comparison between book values and fair values, is given in the table below (excluding tax and social security receivables and payables):

In millions of euros	06/30/2026						
	Assets at fair value through profit or loss (excl. derivatives)	Shares in non-consolidated companies with change in fair value through other comprehensive income	Receivables, payables and borrowings at amortized cost	Derivative instruments	Book value	Fair value	Level
Financial assets							
Shares in non-consolidated companies		111.6			111.6	111.6	1–3
Other non-current financial assets			9.5		9.5	9.5	-
Other non-current assets			11.2		11.2	11.2	
Derivative instruments – assets				5.6	5.6	5.6	2
Trade receivables			715.3		715.3	715.3	-
Other receivables			23.8		23.8	23.8	-
Cash and cash investments	657.7				657.7	657.7	1
TOTAL FINANCIAL ASSETS	**657.7**	**111.6**	**759.8**	**5.6**	**1534.7**	**1534.7**	
Financial liabilities							
Bond issue (a)			55.0		55.0	55.0	1
Other financing facilities			133.6		133.6	133.6	2
Derivative instruments – liabilities				5.6	5.6	5.6	2
Borrowings – current portion			233.2		233.2	233.2	2
Trade payables			252.1		252.1	252.1	-
Other current liabilities			51.5		51.5	51.5	-
TOTAL FINANCIAL LIABILITIES	**-**	**-**	**725.4**	**5.6**	**731.0**	**731.0**	

(a) The book value of bond issues is shown net of issue fees and premiums.

Levels 1 to 3 correspond to the fair value hierarchy as defined by IFRS 13 (see Note 27.1 to the consolidated financial statements at December 31, 2025).

In practice, financial assets and liabilities at fair value essentially concern certain securities, cash investments and derivative instruments. In other cases, fair value is shown in the table above for information purposes only.

As a reminder, shares in non-consolidated companies are recognized at fair value except where this cannot be reliably determined.

No level in the fair value hierarchy is shown when the net book value approximates fair value.

At December 31, 2025, the breakdown of assets and liabilities was as follows:

	12/31/2025						
In millions of euros	Assets at fair value through profit or loss (excl. derivatives)	Shares in non-consolidated companies with change in fair value through other comprehensive income	Receivables, payables and borrowings at amortized cost	Derivative instruments	Book value	Fair value	Level
Financial assets							
Shares in non-consolidated companies		113.3			113.3	113.3	1–3
Other non-current financial assets			15.4		15.4	15.4	-
Other non-current assets			10.3		10.3	10.3	
Derivative instruments – assets				5.5	5.5	5.5	2
Trade receivables			766.3		766.3	766.3	-
Other receivables			15.5		15.5	15.5	-
Cash and cash investments	569.8				569.8	569.8	1
TOTAL FINANCIAL ASSETS	**569.8**	**113.3**	**807.5**	**5.5**	**1496.1**	**1496.1**	
Financial liabilities							
Bond issue (a)			199.9		199.9	199.9	1
Other financing facilities			130.1		130.1	130.1	2
Derivative instruments – liabilities				5.5	5.5	5.5	2
Borrowings – current portion			131.4		131.4	131.4	2
Trade payables			262.1		262.1	262.1	-
Other current liabilities			68.9		68.9	68.9	-
TOTAL FINANCIAL LIABILITIES	**-**	**-**	**792.4**	**5.5**	**797.9**	**797.9**	

(a) *The book value of* the bond issue is shown net of issue fees and premiums.

Movements in financial instruments whose fair value was determined using Level 3 inputs under the IFRS 13 hierarchy (see Note 27.2 to the consolidated financial statements at December 31, 2025) were as follows at June 30, 2026:

DECEMBER 31, 2025	**26.2**
Change from level 3 to 2	
Gains and losses recognized in income	
Gains and losses recognized in other comprehensive income	0.1
Acquisitions	
Disposals	
Changes in the scope of consolidation	0.0
Foreign exchange and other	0.1
JUNE 30, 2026	**26.4**

20.4. COUNTRY RISK

The Group's commercial business is mainly located in the United States (44% of revenue), France (6%), China (4%), Germany (4%), Italy (3%), India (3%) and Spain (3%). No other country represents more than 3% of the Company's revenue.

20.5. CREDIT RISK

With revenue in more than 160 countries from government organizations and private customers, bioMérieux is exposed to a risk of non-payment of its receivables.

Management of credit risk includes prior examination of the financial position of customers in order to determine a credit limit, establishment of specific guarantees or insurance, and monitoring of payment deadlines and late payments.

The Group's policy in terms of impairment of trade receivables is described in Note 9 to the consolidated financial statements at December 31, 2025.

21. OFF-BALANCE SHEET COMMITMENTS

There were no material changes in off-balance sheet commitments during the first half of 2026 (see Note 29 to the consolidated financial statements at December 31, 2025).

For commitments related to derivative instruments, see Note 20.3.

22. TRANSACTIONS WITH RELATED PARTIES

Transactions with related parties continued on the same basis as in 2025 without any significant developments (see Note 30 to the consolidated financial statements at December 31, 2025).

23. SUBSEQUENT EVENTS

Buyout of non-controlling interests in Suzhou Hybiome Biomedical Engineering Co. Ltd.

In July 2026, bioMérieux acquired an additional stake in Suzhou Hybiome Biomedical Engineering Co. Ltd for approximately €0.5 million. Its stake in Suzhou Hybiome Biomedical Engineering Co. Ltd increased from 95.9% at June 30, 2026 to 97.7% at July 31, 2026.

24. ALTERNATIVE PERFORMANCE INDICATORS

The Group uses alternative performance indicators that are not defined by accounting standards, such as EBITDA and free cash flow as defined in Note 12, as well as contributive operating income before non-recurring items and adjusted net earnings per share.

Contributive operating income before non-recurring items corresponds to operating income before non-recurring items (see Note 2.3) excluding amortization and impairment of intangible assets related to acquisitions and acquisition-related costs (see Note 15).

In millions of euros	**2026 (6 months)**	**2025 (6 months)**
OPERATING INCOME	**299.7**	**209.2**
Other non-recurring income and expenses	0.6	0.5
OPERATING INCOME BEFORE NON-RECURRING ITEMS (a)	**299.1**	**208.7**
Amortization and impairment of intangible assets related to acquisitions and acquisition-related costs (b)	-14.2	-163.2
CONTRIBUTIVE OPERATING INCOME BEFORE NON-RECURRING ITEMS (a-b)	**313.3**	**371.9**

Adjusted diluted (net) earnings per share corresponds to the diluted (net) earnings per share (see Note 10.3) adjusted to include amortization and impairment losses on intangible assets related to acquisitions (see Note 15) and other non-recurring income and expenses from operations (see Note 16).

In millions of euros	**2026 (6 months)**	**2025 (6 months)**
Net income attributable to the parent company	**226.1**	**161.0**
Restructuring costs (net reversals of provisions, excluding miscellaneous expenses)	0.6	
Theoretical tax impact	*-0.2*	
Impairment losses of Reveal technology		-145.5
Tax impact on the impairment losses of Reveal technology.		34.9
Amortization of intangible assets related to acquisitions	-12.8	-16.6
Theoretical tax impact on amortization of intangible assets related to acquisitions	*3.0*	*4.0*
Adjusted net income	**235.5**	**284.2**
Adjusted diluted (net) earnings per share	**€ 1.99**	**€ 2.39**

II. INTERIM MANAGEMENT REPORT AT JUNE 30, 2026

25. SIGNIFICANT EVENTS OF THE FIRST HALF

25.1. NEW PRODUCTS

bioMérieux acquires Accellix
On January 22nd, 2026 bioMérieux acquired Accellix, a US company specializing in rapid, automated flow cytometry solutions for cell and gene therapy quality control. With this strategic transaction, bioMérieux strengthens its Pharmaceutical Quality Control activity and invests in innovative solutions that will support the growing advanced therapy market and improve patient outcomes worldwide.

bioMérieux launches SMARTBIOME™ to help food manufacturers gain deeper insights into spoilage and protect product quality
In February 2026, bioMérieux announced the launch of SMARTBIOME™, an innovative solution designed to help food manufacturers better understand, control and prevent microbiological spoilage. By combining high-precision DNA sequencing, advanced bioinformatics and bioMérieux's microbiology expertise, SMARTBIOME™ provides actionable insights to protect product quality, reduce waste and better preserve consumer safety.

bioMérieux receives IVDR CE Marking for two SPOTFIRE® panels to strengthen near-patient respiratory and sore throat diagnostics across Europe
In March 2026, bioMérieux announced that its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat plus (R/ST*plus*) Panel and BIOFIRE® SPOTFIRE® Respiratory/Sore Throat plus (R/ST*plus*) Panel Mini have been CE-marked under the IVDR. The certification includes conformity assessment for near-patient testing, enabling its use outside traditional laboratories, directly at the point of care. These multiplex PCR tests can simultaneously detect the most common pathogens responsible for respiratory and sore throat infections, within a time frame aligned with a typical patient visit.

bioMérieux launches the BIOFIRE® SPOTFIRE® molecular testing solution for the pharmaceutical industry, redefining rapid mycoplasma testing
On April 9th, 2026, bioMérieux announced the launch of BIOFIRE® SPOTFIRE® for pharmaceutical industries. This platform introduces a simple, small and smart approach to mycoplasma detection, helping biopharmaceutical manufacturers strengthen quality control, accelerate decision-making, and protect patients.

bioMérieux invests in France with a new facility to manufacture innovative diagnostics for the European market
On May 29, 2026, bioMérieux announced a strategic investment of more than €250 million to build a new manufacturing facility in France (La Balme-les-Grottes, Isère) dedicated to the production of PCR tests from its BIOFIRE® range. The project is expected to create approximately 400 jobs over time. This new facility will help secure the supply of essential diagnostic solutions for the European market while enhancing the resilience of healthcare systems in addressing infectious diseases threats.

bioMérieux introduced Salmonella testing kit on GENE-UP® TYPER to support root cause analysis in the food industry
On June 18, 2026, bioMérieux introduced the launch of GENE-UP® TYPER SLM, a new real-time PCR solution supporting rapid root cause analysis by discriminating Salmonella in the food industry environments. This new assay specifically targets Salmonella enterica subspecies enterica, the subspecies most frequently isolated in human salmonellosis cases and in food-related incidents.

bioMérieux filed a dual 510(k)/CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
On June 26, 2026, bioMérieux submitted a dual 510(k)/CLIA Waiver application to the U.S. Food and Drug Administration (FDA) for the BIOFIRE® SPOTFIRE® Vaginitis (VG) Panel. This automated, multiplex PCR test panel reports 8 results, including bacterial vaginosis, yeast and parasite pathogens, with one swab, in about 20 minutes to align within a typical patient's visit timeframe. With this submission, bioMérieux is intending to expand into women's and sexual health, bringing rapid

and accurate diagnostics closer to patients. The BIOFIRE® SPOTFIRE® VG Panel aims to support timely treatment decisions and delivers a clear and dignified diagnostic experience, which may be associated with improved patient management.

bioMérieux submitted 510(k) to U.S. FDA for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens
On June 30, 2026, bioMérieux announced the submission of the BIOFIRE® FILMARRAY® Gastrointestinal 1.1 (GI1.1) Panel and the BIOFIRE® FILMARRAY® Gastrointestinal 1.1 (GI1.1) Panel Mid to the U.S. Food and Drug Administration (FDA) for 510(k) review. These PCR molecular panels test 22 and 11, respectively, of the most common bacteria, viruses, and parasites associated with gastroenteritis, all from one sample, with results available in approximately one hour. These new versions introduce updated capabilities, including enhanced norovirus detection, further strengthening assay specificity.

CE-Marking for the SPINCHIP® Analyzer and its first assay, SPINCHIP® hs-cTnI.
In July 2026, bioMérieux completed the IVDR CE-Marking for the SPINCHIP® Analyzer and its first assay, SPINCHIP® hs-cTnI. SPINCHIP® is a breakthrough immunoassay diagnostics platform that delivers laboratory quality performance at the Point Of Care. It will complement bioMérieux's existing portfolio and strengthen bioMérieux's presence in the rapidly growing point-of-care segment. The SPINCHIP® hs-cTnI assay enables the high-sensitivity measurement of cardiac troponin I for patients with suspected myocardial infraction. The commercial launch, in Europe, is planned for later in 2026.

26. FINANCIAL SUMMARY

Consolidated data In € million	**H1 2026**	H1 2025	% Change *As reported*	% Change *At constant exchange rates and scope of consolidation*
Net Sales	**1,965**	**2,044**	*-3.9%*	*+0.2%*
Contributive operating income before non-recurring items	**313**	**372**	*-15.7%*	*-4.9%*
% sales	*15.9%*	*18.2%*		
Operating income	**299**	**209**	*+43.3%*	*+62.9%*
Net income, group share	**226**	**161**	*+40.6%*	*+62.5%*
Diluted net income per share	**1.91€**	**1.35€**		
Adjusted Net Income	**236**	**284**		
Adjusted Earnings Per Share (diluted)	**1.99€**	**2.39€**	*-17.0%*	*-4.0%*

EBITDA	**440**	**495**	*-11.0%*	*-1.8%*
Free Cash Flow	**299**	**170**	*+75.8%*	

	H1 2026	FY 2025	% Change *As reported*
Net Cash Position	**236**	**108**	*+117.6%*

27. BUSINESS REVIEW

27.1. ACTIVITY

NB: Unless otherwise stated, sales growth is expressed at constant exchange rates and scope of consolidation (like-for-like).

Consolidated sales amounted to €1,965 million in the first half of 2026 versus €2,044 million in the same period last year. Organic growth was +0.2%, while reported growth stood at -3.9%, impacted by an unfavorable currency effect of -€87 million, mainly driven by the depreciation of the US dollar, the Indian Rupee, the Japanese Yen and the Argentinian Peso.

Evolution of sales

In € million

SALES – SIX MONTHS ENDED JUNE 30, 2025	2,043.8	
Currency effect	-87.3	-4.3%
Changes in scope of consolidation[1] & hyperinflation[2]	+4.1	+0.2%
Organic growth (at constant exchange rates and scope of consolidation)	**4.0**	**+0.2%**
SALES – SIX MONTHS ENDED JUNE 30, 2026	**1,964.6**	**-3.9%**

Analysis of sales by application

Sales by Application In € millions	**Q2 2026**	Q2 2025	% change as reported	**% change at constant exchange rates and scope of consolidation**	**Six months ended June 30, 2026**	Six months ended June 30, 2025	% change as reported	**% change at constant exchange rates and scope of consolidation**
Clinical applications	**809.6**	786.6	+2.9%	**+4.1%**	**1,634.1**	1,724.4	-5.2%	**-1.1%**
Molecular biology	**384.3**	380.9	+0.9%	**+2.5%**	**809.1**	**902.7**	-10.4%	**-5.4%**
BIOFIRE®	**338.7**	342.8	-1.2%	**+0.4%**	**696.4**	**795.0**	-12.4%	**-7.7%**
SPOTFIRE®	**34.3**	25.1	+36.6%	**+37.7%**	**90.3**	79.4	+13,7%	**+21.8%**
Other Molecular	**11.3**	13.0	-13.5%	**-11.1%**	**22.4**	28.3	-20.6%	**-17.6%**
Microbiology	**337.9**	320.4	+5.4%	**+6.5%**	**652.8**	646.6	+1.0%	**+4.3%**
Immunoassays	**72.3**	74.2	-2.6%	**-1.0%**	**139.4**	149.3	-6.6%	**-3.2%**
Other lines(1)	**15.1**	11.1	+36.8%	**+21.1%**	**32.9**	25.9	+27.0%	**+24.2%**
Industrial Applications(2)	**171.3**	159.3	+7.6%	**+9.3%**	**330.4**	319.4	+3.5%	**+7.2%**
TOTAL SALES	**981.0**	945.9	+3.7%	**+5.0%**	**1,964.6**	2,043.8	-3.9%	**+0.2%**

(1) *Including mainly BioFire Defense and R&D-related revenue arising on clinical applications*

(2) *Including R&D-related revenue arising on industrial applications.*

[1] *As defined in Appendix 1.*

[2] *For those currencies meeting the criteria to be considered hyperinflationary under IAS 29, such as Argentina and Turkey, an IFRS technical adjustment for hyperinflation impact is reflected as FX and therefore excluded from the organic growth calculation. The effect of operational actions taken in these countries such as increased pricing to mitigate the inflationary impact is reflected as part of the organic growth.*

Q2 26 vs Q2 25 like-for-like evolutions by application:

- **CLINICAL APPLICATIONS sales** increased by 4.1%, reaching €810 million:
  - In **molecular** biology:
    - **BIOFIRE® non-respiratory** panels sales grew by 7%, driven by growth across all panels and all regions;
    - **BIOFIRE® respiratory** panels sales declined by 6%, reflecting a significantly lower epidemiology compared with the prior year;
    - **SPOTFIRE®** generated €34 million in sales, representing 38% year-on-year growth, despite a lower respiratory epidemiology, an evolution in the mix, and changes in the reimbursement policy in Japan. The SPOTFIRE® installed base exceeded 7,200 instruments as of June 30, 2026, following 400 new instrument installations during the quarter.
  - **Microbiology** sales grew by 6.5%, driven by an improvement in China and in instruments' sales versus the previous quarter, along with sustained momentum in reagents sales, particularly within the BACT/ALERT® range, and a positive price effect.
  - **Immunoassays** sales declined by 1%, still impacted by China's volume-based procurement policy and lower global VIDAS® PCT sales. Excluding these two factors, Immunoassays delivered close to mid-single digit sales growth with solid dynamics in India and Africa.
- **INDUSTRIAL APPLICATIONS** sales rose by 9% to €171 million, reflecting sustained momentum in reagents sales, notably in the molecular biology and flow cytometry ranges and a positive price effect.

Analysis of sales by region

Sales by Region In € millions	**Q2 2026**	Q2 2025	% change as reported	**% change at constant exchange rates and scope of consolidation**	**Six months ended June 30, 2026**	Six months ended June. 30, 2025	% change as reported	**% change at constant exchange rates and scope of consolidation**
North America	**432.3**	416.4	+3.8%	**+5.9%**	**888.3**	960.1	-7.5%	**-1.3%**
Latin America	**73.8**	66.5	+10.9%	**+6.3%**	**142.4**	129.1	+10.3%	**+10.8%**
EMEA [(1)]	**330.9**	317.0	+4.4%	**+4.3%**	**646.8**	637.7	+1.4%	**+1.8%**
Asia Pacific	**144.0**	146.0	-1.3%	**+3.0%**	**287.1**	316.8	-9.4%	**-2.7%**
TOTAL SALES	**981.0**	945.9	+3.7%	**+5.0%**	**1,964.6**	2,043.8	-3.9%	**+0.2%**

[(1)] *Including Europe, the Middle East and Africa.*

Q2 26 vs Q2 25 like-for-like trends per region:

North America (44% of the consolidated total) delivered solid sales growth of nearly +6%, supported by solid reagents sales across SPOTFIRE®, microbiology, BIOFIRE® non-respiratory panels and industrial applications ranges. This performance was partly offset by a decline in BIOFIRE® respiratory panels, because of lower respiratory epidemiology, and in immunoassays sales.

Latin America (7% of the consolidated total) recorded +6% sales growth, driven by double digit sales growth in microbiology, BIOFIRE® non respiratory panels and SPOTFIRE®. On the opposite, BIOFIRE® respiratory panels sales were down double digit, impacted by lower respiratory epidemiology.

Europe – Middle East – Africa region (34% of group sales) recorded 4% sales growth. Performance was driven by microbiology, BIOFIRE® non-respiratory panels and SPOTFIRE® sales. This was partially offset by lower sales of BIOFIRE® respiratory panels driven by lower respiratory epidemiology.

Asia-Pacific region (15% of group's sales) sales were up +3% driven by a strong dynamic in Industrial Applications segment, a sustained growth in immunoassays in India and a slight improvement in China which were partly offset by decline in BIOFIRE® respiratory sales on lower respiratory epidemiology and SPOTFIRE® sales impacted by change in reimbursement policy in Japan.

27.2. FINANCIAL HIGHLIGHTS

CONSOLIDATED INCOME STATEMENT

- **Contributive operating income before non-recurring items (CEBIT)** [3]

  For the six months ending June 30, 2026, reported CEBIT decline by -16% year-on-year to €313 million, representing 15.9% of total sales. At constant exchange rates and scope of consolidation, CEBIT decreased -4.9% compared with the first half of 2025.

  - **Gross profit** amounted to €1,098 million, decreased by -1% versus H1 2025 at **constant** exchange rates and scope of consolidation, mainly driven by unfavorable product mix, investments in manufacturing projects and higher transport costs due to Middle East events. The impact of tariffs was almost neutral year-on-year, with the extra tariffs' charges being offset by the reimbursement of the tariffs paid in 2025.

  - **Selling, general and administrative expenses** amounted to €544 million, a 2% like for like decrease versus H1 2025, reflecting lower variable compensation and positive impact of efficiency measures.

  - **R&D expenses** amounted to €257 million, or 13.1% of sales, compared with €249 million and 12.2% one year earlier, a +5% increase on a like-for-like basis, with increased investments in molecular franchise, SPINCHIP® technology and microbiology.

- **Operating income before non-recurring items**

  Amortization and impairment of acquisition-related intangible assets, along with acquisition costs, amounted to €14 million in H1 2026, down from €163 million in first-half 2025, which was impacted by the €146 million partial impairment of the VITEK® REVEAL™ (fast AST solution) technology.

  As a result, the Group ended the first half of 2026 with an **operating income** of €299 million, up 43.3% compared to the €209 million reported during the same period one year earlier.

- **Net income of consolidated companies**

  - **Net financial expenses** amounted to €5 million in H1 2026, compared with net financial income of €4 million in H1 2025, reflecting the adverse impact on cash positions of the increase of the euro against most currencies, particularly the U.S. dollar.

  - The **Company's effective tax rate** stood at 23.4% as of June 30, 2026.

  - **Net income, Group share,** amounted to €226 million in the first half of 2026, up 41%.

---

[3] *As defined in Appendix 1.*

- **Adjusted Net Income**[4]**,** which excludes the amortization and impairment of **acquired** intangible assets, as well as the effects of significant non-recurring operations, including restructuring operations, and their related tax impacts, reached €236 million, down 17% versus H1 2025.

Adjusted diluted earnings per share[4] for H1 2026 reached €1.99, a -4% organic and -17% reported decline versus H1 2025, fully in line with the evolution of the CEBIT.

CASH MANAGEMENT AND FINANCING

Free cash flow

EBITDA[4] came to €440 million in first-half of 2026, or 22.4% of sales, down 2% on an organic basis, and down 11% on a reported basis from the €495 million reported for the same period one year earlier in line with the evolution of the contributive operating income before non-recurring items.

Operating working capital decreased by €19 million in the first half of 2026. This evolution was primarily the result of the following items:

a. trade receivables decreased by €63 million mainly driven by sales activity and thanks to an efficient cash collection in the US;
b. inventories reduced by €7 million like-for-like during the period, driven by a decrease in raw materials inventory in the US;
c. other working capital requirement items decreased by €42 million, primarily due to annual bonuses payments.

Income tax paid represented €28 million in H1 2026, a decrease from the €123 million paid in the first six months of 2025, reflecting the positive cash flow impact of the U.S. tax legislation evolution that came into effect in July 2025.

Capital expenditure represented 7.1% of sales or €139 million in the first half of 2026, down 9% compared to the level recorded in the first half of 2025. Most of these investments were made in the U.S. and French manufacturing sites, to increase their capacity and automation, and in the placement of new instruments.

As a result, **free cash flow** reached €299 million in the first half of 2026, a 76% increase compared with €170 million in the first half of 2025.

Business development & financing operations

In January 2026, bioMérieux acquired the remaining 90% equity interest in **Accellix**, a privately held U.S. company that develops a rapid, automated flow cytometry solutions for cell and gene therapy quality control. The cash outflow amounted to approximately €28 million.

[4] *As defined in Appendix 1.*

Change in net cash position[5]

A **dividend** of €115 million was paid in the first half of 2026, i.e. €0.98 per share, a +9% increase versus the €0.90 per share distributed one year earlier.

As a result, consolidated **net cash position** came to €236 million as of June 30, 2026, versus a net cash position of €108 million as of December 31, 2025. This net cash position includes the discounted liability related to leases amounting to €155 million (IFRS16).

28. SUBSEQUENT EVENTS

CE-Marking for the SPINCHIP® Analyzer and its first assay, SPINCHIP® hs-cTnI. In July 2026, bioMérieux completed the IVDR CE-Marking for the SPINCHIP® Analyzer and its first assay, SPINCHIP® hs-cTnI. SPINCHIP® is a breakthrough immunoassay diagnostics platform that delivers laboratory quality performance at the Point Of Care. It will complement bioMérieux's existing portfolio and strengthen bioMérieux's presence in the rapidly growing point-of-care segment. The SPINCHIP® hs-cTnI assay enables the high-sensitivity measurement of cardiac troponin I for patients with suspected myocardial infraction. The commercial launch, in Europe, is planned for later in 2026.

29. RISK FACTORS

The principal risks to which bioMérieux is exposed are set out in the 2025 Universal Registration Document filed with the French financial markets authority on March 16, 2026 (see sections 2 and 6.1 – Note 28 to the consolidated financial statements at December 31, 2025). Notes 15 (Provisions – Contingent assets and liabilities) and 28 (Exchange rate and market risk management) to the interim consolidated financial statements at June 30, 2025 shown in this report also set out the risks to which the Company could be exposed during the second half of 2025. Lastly, other risks and uncertainties of which bioMérieux is not aware at this time or which it considers not material could also adversely affect its business.

30. PRINCIPAL TRANSACTIONS WITH RELATED PARTIES

Transactions with related parties continued on the same basis as in 2025 without any significant developments (see Note 30 to the consolidated financial statements at December 31, 2025 in section 6 of the 2025 Universal Registration Document).

31. OUTLOOK

Based on its first-half 2026 performance, bioMérieux confirms its 2026 full year guidance for both sales and CEBIT growth:

- **2026 sales are expected to grow by +3% to +5%** at constant exchange rates and scope of consolidation;
- **2026 CEBIT should grow by +0% to +10%** at constant exchange rates and scope of consolidation;
- The **2026 full year currency effect** on CEBIT is now expected to reach approximately -€40 million to -€50 million (previously -€50 million to -€60 million).

[5] *As defined in Appendix 1.*

III. STATUTORY AUDITORS' REPORT

"Statutory Auditors' report on the interim financial information"

bioMérieux

Period from January 1 to June 30, 2026

Statutory auditors' report on the interim financial information

GRANT THORNTON
French member of Grant Thornton International
Cité Internationale
44, quai Charles-de-Gaulle
CS 60095
69463 Lyon CEDEX 06
SAS with share capital of €2,297,184
632 013 843 R.C.S. Nanterre

Statutory Auditor
Member of the Compagnie Régionale des
Commissaires aux Comptes de Versailles et du Centre

ERNST & YOUNG et Autres
Tour Oxygène
10–12, boulevard Marius Vivier Merle
69393 Lyon CEDEX 03
SAS with variable capital
438 476 913 R.C.S. Nanterre

Statutory Auditor
Member of the Compagnie Régionale des
Commissaires aux Comptes de Versailles et du Centre

bioMérieux

Period from January 1 to June 30, 2026

Statutory auditors' report on the interim financial information

To the Shareholders,

In compliance with the assignment entrusted to us by your Annual General Meetings and in accordance with the requirements of Article L. 451-1-2 III of the French Monetary and Financial Code (*Code monétaire et financier*), we hereby report to you on:

- the review of the accompanying condensed interim consolidated financial statements of bioMérieux, for the period from January 1 to June 30, 2026;
- the verification of the information presented in the Interim Management Report.

These condensed interim consolidated financial statements are the responsibility of the Board of Directors. Our role is to express a conclusion on these financial statements based on our review.

1. Conclusion on the Financial Statements

We conducted our review in accordance with professional standards applicable in France.

A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with professional standards applicable in France and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review, nothing has come to our attention that causes us to believe that the condensed interim consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34 – standard of the IFRS as adopted by the European Union applicable to interim financial information.

2. Specific Verification

We have also verified the information presented in the Interim Management Report on the condensed interim consolidated financial statements subject to our review.

We have no matters to report as to its fair presentation and consistency with the condensed interim consolidated financial statements.

Lyon, July 29, 2026

The Statutory Auditors

GRANT THORNTON *French member of Grant Thornton International*	ERNST & YOUNG et Autres
Françoise Méchin	Sylvain Lauria

IV. STATEMENT BY THE INDIVIDUAL RESPONSIBLE FOR THE INTERIM FINANCIAL REPORT

STATEMENT BY THE PERSON RESPONSIBLE FOR THE HALF-YEAR FINANCIAL REPORT

I, hereby, certify that, to the best of my knowledge, the consolidated financial statements for the past half year have been prepared in accordance with the applicable accounting standards and give a true and faire view of the assets, liabilities, financial position and results of the Company and the consolidated Group as a whole, and that the interim management report on pages 55 *et seq.* provides a fair view of the significant events that took place during the first six months of the fiscal year, their impact on the interim financial statements and the principal transactions with related parties, as well as a description of the principal risks and uncertainties for the remaining six months of the fiscal year.

Marcy l'Etoile, July 30, 2026

Chief Executive Officer

Pierre Boulud

Appendix 1: GLOSSARY & DISCLAIMER

DEFINITIONS

Adjusted diluted Earnings Per Share (EPS): Adjusted net income divided by the number of shares used in the basic earnings calculation, increased by the weighted average number of potential shares to be issued that would have a dilutive effect on earnings. The number considered shares was 118,367,846 as of December 31, 2025, compared with 118,905,491 as of December 31, 2025.

Adjusted Net Income: Net income adjusted for the amortization and impairment of acquired intangible assets, as well as the effects of significant non-recurring operations, including restructuring operations, and their related tax impacts. The Company considers that this indicator provides the best possible representation of the financial performance of the Company. The reconciliation between the Net Income and the Adjusted Net Income is presented in note #24 of the June 30, 2026 financial report and in the appendix #4 of this document.

Changes in the scope of consolidation: The effects of changes in the scope of consolidation are determined:

- for acquisitions for the period, by deducting from sales and operating expenses for the period the amount of sales and operating expenses made during the period by the entities acquired from their entry into the scope of consolidation;
- for acquisitions of the previous period, by deducting from sales and operating expenses for the period the amount of sales and operating expenses made during the months in which the acquired entities were not consolidated during the previous period;
- for disposals for the period by adding to sales and operating expenses for the period the amount of sales and operating expenses made by the entities sold the previous period, during the months in which these entities are no longer consolidated over the current period;
- for disposals for the previous period, by adding to the sales and operating expenses of the period the sales and operating expenses made during the preceding period by the entities sold.

Currency effect: established by comparing the actual numbers converted at the average exchange rates of the current year to the actual numbers converted at the average exchange rates of the comparison period. In practice, those rates are either average rates communicated by the ECB, or hedged rates if hedging instruments have been set up.

Contributive operating income before non-recurring items (CEBIT): operating income before non-recurring items, excluding items relating to the amortization and impairment of intangible assets related to acquisitions and acquisition-related costs. The Company considers that this indicator provides the best possible representation of the operational performance of the Company. The reconciliation between the operating income before non-recurring items and the contributive operating income before non-recurring items is presented in note #12 of the June 30, 2026 financial report.

Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA): sum of the contributive operating income before non-recurring items, depreciation and amortization. The reconciliation between the Contributive operating income and EBITDA is presented in note #12 of the June 30, 2026 financial report.

Free Cash Flow Generation: cash flow from operations plus cash flow from capital expenditure excluding net cash from acquisitions and disposal of subsidiaries. This indicator is presented in the consolidated cash flow statement in the December 31st 2025 financial report.

Net debt / Net cash position: sum of cash and cash equivalents less committed debt and bank overdrafts and other uncommitted borrowings. This indicator is presented in the note #12 of the June 30, 2026 financial report.

Operating income before non-recurring items: recurring income less recurring expenses and amortization and impairment of intangible assets related to acquisitions and acquisition-related costs. Non-recurring expenses and income are not included.

DISCLAIMER

The forward-looking statements contained in this document are based, entirely or partially, on assessments or judgments that may change or be modified, due to uncertainties and risks related to the Company's economic, financial, regulatory and competitive environment, notably those described in the 2025 Registration Document. Accordingly, the Company cannot give any assurance nor make any representation as to whether the objectives will be met. The Company does not undertake to update or otherwise revise any forecasts or objectives presented herein, except in compliance with the disclosure obligations applicable to companies whose shares are listed on a stock exchange.